Protocol I4V-M C-JAHH 
A Randomized, Double-B lind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricit inib 
in Patients with Systemic Lupus Erythematosus (SLE) 
[STUDY_ID_REMOVED] 
Approval Date: 11-D ec-2015 
I4V-MC-JAHHClinical Protocol Page 1
LY3009104Protocol I4V-MC-JAHH
A Randomized, Double -Blind, Placebo -Controlled, Parallel -
Group, Phase 2 Study  of Baricitinib in Patients with Sy stemic 
Lupus Ery thematosus (SLE)
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involve d in the clinical investigation of 
baricitinib (LY3009104 ), unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities :  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure .  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release .  In 
the United States, this document is subject to Freedom of Information Act (FOI A) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Baricitinib (LY3009104 )
Study I4V -MC-JAHH is a Phase 2 ,multicenter, randomized, double -blind, placebo -
controlled, parallel -group, outpatient, 24 -week study designed to evaluat ethe efficacy and 
safety of baricitinib 4-mg and 2-mg in patients with SLE receiving standard therap y.
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly on date provided below.
Approval Date: 11-Dec-2015 GMT
I4V-MC-JAHHClinical Protocol Page 2
LY3009104Table of Contents
Section Page
1. Protocol  Synopsi s................................................................................................................ 9
2. Introduction ...................................................................................................................... 12
2.1. Backgro und.................................................................................................................. 12
2.2. Study  Rati onale ............................................................................................................ 14
2.3. Benefit/Risk Assessment .............................................................................................. 15
3. Object ives and Endpo ints.................................................................................................. 16
4. Study  Design ..................................................................................................................... 18
4.1. Overview of Study  Design ........................................................................................... 18
4.2. End of Trial Definit ion.................................................................................................19
4.3. Scientific Rationale for Study  Design ........................................................................... 19
4.4. Justification for Dose ................................................................................................... 21
5. Study  Popul ation............................................................................................................... 22
5.1. Inclusio nCriteria.......................................................................................................... 22
5.1.1. Entry  Criteria....................................................................................................... 22
5.1.2. Enrollment Criteria .............................................................................................. 22
5.2. Exclusio n Cri teria........................................................................................................ 23
5.2.1. Entry  Criteria....................................................................................................... 23
5.2.2. Enrollment Criteria .............................................................................................. 27
5.3. Screen Failures ............................................................................................................. 30
5.4. Lifest yle and/or Dietary Requirements ......................................................................... 30
6. Treatment .......................................................................................................................... 31
6.1. Treatments Administered ............................................................................................. 31
6.2. Method of Treatment Assignment ................................................................................ 31
6.2.1. Selection and Timing o f Doses ............................................................................. 31
6.3. Blinding ....................................................................................................................... 32
6.4. Packaging and Labeling ............................................................................................... 32
6.5. Preparati on/Handling/Storage ....................................................................................... 32
6.6. Dose Modificat ion........................................................................................................ 33
6.7. Treatment Compliance .................................................................................................33
6.8. Concomitant Therapy ................................................................................................... 33
6.9. Treatment after Study  Com pletion................................................................................ 34
6.9.1. Continued Access .................................................................................................34
7. Discontinuati on Cri teria .................................................................................................... 35
7.1. Discontinuati on from Study  Treatm ent......................................................................... 35
I4V-MC-JAHHClinical Protocol Page 3
LY30091047.1.1. Interrupti on of  Investi gational Product .................................................................35
7.1.2. Perm anent Discont inuat ion of Investigation Product ............................................ 36
7.1.3. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 37
7.1.4. Patients Lost to Follow -Up................................................................................... 38
8. Study  Assessments and Procedures ................................................................................... 39
8.1. Efficacy Assessments ................................................................................................... 39
8.1.1. Primary Efficacy  Assessment Scal e...................................................................... 39
8.1.1.1. SLEDAI -2K................................................................................................... 39
8.1.2. Secondary  Efficacy  and Expl oratory  Assessments ................................................ 39
8.1.2.1. SLE Responder Index -4 (SRI -4)..................................................................... 39
8.1.2.2. Physician’s Global Assessment of Disease Activit y........................................ 39
8.1.2.3. BILAG2004 ................................................................................................... 40
8.1.2.4. 28 Tender Joint Coun t & 28 Swollen Jo int Count ........................................... 40
8.1.2.5. Cutaneous Lupus Ery thematosus Di sease Area and 
Severit y Index (CLASI) .................................................................................. 40
8.1.2.6. SLEDAI Flare Index (SFI) .............................................................................. 40
8.1.2.7. SLICC/ACR Damage Index ............................................................................ 40
8.1.3. Appropriateness of Assessments .......................................................................... 41
8.2. Adverse Events ............................................................................................................ 41
8.2.1. Serious Adverse Events ........................................................................................ 41
8.2.2. Adverse Events and Laboratory  Tests of Speci al Interest 
(AESIs) ................................................................................................................ 42
8.2.2.1. Suspected Unexpected Serious Adverse React ions.......................................... 42
8.2.2.2. Reasonably Ant icipated Serious Adverse Events ............................................ 43
8.2.3. Com plaint Handling ............................................................................................. 43
8.3. Treatment of Overdose .................................................................................................43
8.4. Safety Assessments ...................................................................................................... 43
8.4.1. Electrocardiograms .............................................................................................. 43
8.4.2. Vital Signs ........................................................................................................... 43
8.4.3. Laboratory  Tests .................................................................................................. 44
8.4.4. Hepati tis B Vi rus (HBV) DNA Monitoring .......................................................... 44
8.4.5. Chest X -ray and Tuberculosis Test ing.................................................................. 44
8.4.6. Quick Inventory  of Depressive Symptom atology Self-Rated –
16 (QIDS -SR16).................................................................................................... 44
8.4.7. Safety Moni toring ................................................................................................ 45
8.5. Pharmacokinet ics......................................................................................................... 45
8.6. Pharmacodynamics ...................................................................................................... 46
8.7. Genet ics....................................................................................................................... 47
8.7.1. Who le Blood Sample for Pharmacogenet ic Research ........................................... 47
I4V-MC-JAHHClinical Protocol Page 4
LY30091048.8. Biomarkers ................................................................................................................... 47
8.9. Heal th Outcom es.......................................................................................................... 48
8.9.1. Patient’s Gl obal Assessment of Di sease Act ivity.................................................. 48
8.9.2. Brief Pain Inventory  (BPI) –Wo rst Pain Numeric Rating 
Scale (NRS) ......................................................................................................... 48
8.9.3. Brief Pain Inventory  (BPI) –Wo rst Joint Pain NRS ............................................... 48
8.9.4. Brief Fatigue Inventory (BFI) –Worst Fatigue NRS .............................................. 48
8.9.5. Short -Form 36 -item Heal th Survey v2 (SF-
36)..................................................... 49
9. Statistical Considerations and Data Analysis ..................................................................... 50
9.1. Determinat ion of Sample Size ...................................................................................... 50
9.2. General Statist ical Conside rations................................................................................ 50
9.2.1. General Considerations for Analyses .................................................................... 50
9.2.2. Analysis Populat ions............................................................................................ 51
9.2.3. Baseline Definit ion.............................................................................................. 51
9.2.4. Missing Data Imputation ...................................................................................... 51
9.2.5. Adjustment for Mul tiple Com parisons .................................................................. 52
9.2.6. Adverse Events/Laboratory  Resul ts of Special  Interest ......................................... 52
9.3. Treatment Group Comparabilit y................................................................................... 52
9.3.1. Patient Disposi tion............................................................................................... 52
9.3.2. Patient Characteri stics.......................................................................................... 52
9.3.3. Concomitant Therapy ........................................................................................... 52
9.3.4. Treatment Compliance ......................................................................................... 52
9.4. Primary and Secondary  Analyses ................................................................................. 52
9.4.1. Primary Analyses .................................................................................................52
9.4.2. Secondary  Analyses ............................................................................................. 53
9.4.3. Exploratory  Analyses ........................................................................................... 53
9.5. Safety Analyses ............................................................................................................ 54
9.5.1. Adverse Events .................................................................................................... 55
9.5.2. Clinical Laboratory  Tests ..................................................................................... 55
9.5.3. Vital Signs, Physical Findings, and Other Safet y Evaluat ion................................ 56
9.6. Pharmacokinet ic/Pharmacodynamic Analyses .............................................................. 56
9.7. Other Analyses ............................................................................................................. 56
9.7.1. Health Outcom es.................................................................................................. 56
9.7.2. Subgroup Analyses. ............................................................................................. 56
9.8. Interim Analyses .......................................................................................................... 57
10. Study  Governance Considerat ions..................................................................................... 58
10.1. Regulatory  and Ethi cal Considerat ions, Including the Informed 
Consent Process ........................................................................................................... 58
I4V-MC-JAHHClinical Protocol Page 5
LY300910410.1.1. Inform ed Consent .................................................................................................58
10.1.2. Ethical Review ..................................................................................................... 58
10.1.3. Regulatory  Considerat ions................................................................................... 58
10.1.4. Invest igator Informat ion....................................................................................... 59
10.1.5. Protocol  Signatures .............................................................................................. 59
10.1.6. Final Report Signature ......................................................................................... 59
10.2. Data Qualit y Assurance ................................................................................................ 59
10.2.1. Data Capture System ............................................................................................ 60
10.3. Study  and Si te Cl osure .................................................................................................60
10.3.1. Discontinuati on of  Study  Sites............................................................................. 60
10.3.2. Discontinuati on of  the Study ................................................................................ 60
11. References ........................................................................................................................ 61
I4V-MC-JAHHClinical Protocol Page 6
LY3009104List of Tables
Table Page
Table JAHH.1. Object ives and Endpo ints............................................................................... 16
Table JAHH.2. Treatment Regimens ...................................................................................... 31
Table JAHH.3. Criteria for Tem porary  Interrupti on of  Invest igational Product ....................... 35
Table JAHH.4. Study  JAHH Exploratory  Analyses ................................................................ 54
I4V-MC-JAHHClinical Protocol Page 7
LY3009104List of Figures
Figure Page
Figure JAHH.1. Illustrati on of  stud y design for Clinical Protocol I4V -MC-JAHH. .................. 19
I4V-MC-JAHHClinical Protocol Page 8
LY3009104List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 65
Appendix 2. Schedule of Act ivities.................................................................................... 70
Appendix 3. Clinical Laboratory  Tests ............................................................................... 76
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 79
I4V-MC-JAHHClinical Protocol Page 9
LY30091041.Protocol Sy nopsis
Title of Study:
A Randomized, Double -Blind, Placebo -Controlled, Parallel -Group, Phase 2 Study of Baricitinib in Patients with 
Systemic Lupus Erythematosus (SLE)
Rationale: 
Systemic lupus erythematosus (SLE) is achronic, debilitating autoimmune disease that is characterized by the 
presence of autoreactive B cells and elevated levels of autoantibodies, which directly damage the body’s cells and 
tissues.  SLE can affect multiple organ systems simultaneously or sequentially, and follows an unpredictable clinical 
course where periods of relatively stable disease are followed by flares and/or periods of active disease that can 
ultimately lead to irreversible damage to tissues and organ systems. 
Baricitinib is an orally available, selective Janus kinase ( JAK)inhibitor with excellent potency and selectivity for 
JAK1 and JAK2 and less potency for JAK3 or Tyrosine kinase 2 (TYK2 ; Fridman et al. 2010).  This activity profile 
suggests that baricitinib may inhibit cytokines implicated in SLE such as type I interferon ( IFN; JAK1/TYK2), type 
II IFN-γ, interleukin ( IL)-6 (JAK1/JAK2/TYK2), and IL -23 (JAK2/TYK2) as well as other cytokines that may have 
a role in SLE, including granulocyte -macrophage colony stimulating factor (JAK2/JAK2) and IL -12 (JAK2/TYK2).  
The potential impact of baricitinib on the IFN pathway is highl y relevant to SLE, as clinical and preclinical studies 
have established that this pathway is involved in the pathogenesis of SLE .  
Clinical studies have established that baricitinib is effective in autoimmune/autoinflammatory diseases involving the 
joints, skin ,and kidney s.  Baricitinib was effective at reducing swollen and tender joints in patients with rheumatoid 
arthritis (RA; I4V-MC -JADA [Phase 2 ]and I4V -MC -JADW and I4V -MC-JADX [Phase 3 ]), was effective at 
reducing disease severity in patients with moderate to severe plaque psoriasis (Menter et al. 2014 ), and was effective 
at reducing the urinary albumin -to-creatinine ratio (UACR) in patients with diabetic kidney disease (Tuttle et al. 
2015).  The mechanism of action, combined with demonstration of clinical benefit in inflammatory diseases 
involving joints, skin and kidneys, provides the rationale for evaluating baricitinib in SLE .
Objectives/Endpoints:
Objectives Endpoints
Primary
Toevaluate the effect of baricitinib 4-mgdaily  (QD) or
2-mg QD compared to placebo onremissio n of SLE 
arthritis and/or rash in patients with SLE receiving 
concomitant standard therapy over 24 weeks .Change in the proportion of patients who achieve 
remission of arthritis and/or rash as defined by the 
Systemic Lupus Erythematosus Disease Activity Index 
2000 
(SLEDAI -2K) at Week 24 compared to baseline.
Secondary
To evaluate the effect of baricitinib 4-mgQDor2-mg
QDcompared to placebo on overall SLE disease 
activity  in patients with SLE receiving concomitant 
standard therapy over 24 weeks.Change in the p roportion of patients achieving SLE 
Responder Index (SRI)-4 response at Week 24 
compared to baseline.  SRI -4 response is defined as: 
oReduction of ≥4 points from baseline in 
SLEDAI -2Kscore; 
oNo new British Isles Lupus Assessment Group 
(BILAG )A or no mo re than 1 new BILAG B 
disease activity scores; and
oNo worsening (defined as an increase of 
≥0.3 points [10 mm] f rom baseline) in the 
Physician ’sGlobal Assessment of Disease 
Activity .
I4V-MC-JAHHClinical Protocol Page 10
LY3009104Objectives Endpoints
Change in the proportion of patients achieving a 
reductio n of ≥4 points from baseline in SLEDAI -2K 
score at Week 24 compared to baseline.
Change in SLEDAI -2K total score at Week 24 
compared to baseline.
To evaluate the effect of baricitinib 4-mgQDor2-mg
QDcompared to placebo on thePatient ’s Global 
Assessment of Disease Activity  in patients with SLE 
receiving concomitant standard therapy over 24 weeks.Change in Patient’s Global Assessment of Disease 
Activity  at Week 24 compared to baseline .
To characterize the pharmacokinetics (PK) of 
baricitinib 4-mg QDor2 -mgQDin patients with SLE 
receiving concomitant standard therapy over 24 weeks.Plasma baricitinib concentrations will be analyzed 
using a population PK (popPK) approach .
Summary of Study Design:  
Study I4V -MC -JAHH (JAHH) is a Phase 2 multicenter, randomized, double -blind, placebo -controlled, parallel -
group, outpatient, 24 -week study evaluating the efficacy and safety of baricitinib 4-mg and 2-mgin patients with 
SLE receiving standard therapy.
Treatment Group s and Duration:  
Patients will be randomized at Week 0 to 1 of 3 treatment groups , baricitinib 4-mgdaily , baricitinib 2-mgdaily , or 
placebo.  The maximum total study duration will be up to 34 weeks over 3 periods (Screening Period :  up to 6 weeks 
prior to randomization; Double -Blinded Treatment Period:  24 weeks; Follow -upPeriod :  4 weeks after the last dose 
of investigational product ).
Number of Patient s: 
This study will include a pproximately 300patients with SLE who will be randomized 1:1:1 to 1 of2 dose groups of 
baricitinib or placebo ( 100patients per treatment group).
Statistical Analysis:
Unless otherwise specified, the efficacy , health outcome s, and safety analy ses will be conducted on the modified 
intent -to-treat (mITT) population .
Comparisons between baricitinib 4-mgor 2-mg and placebo will be performed for all analyses in the treatment 
period. Baseline will be defined as the last available value before the first dose of investigational product for both 
efficacy and safety analyses.
Treatment comparisons of categorical efficacy variables will be made using a logistic regression analysis with 
treatment, baseline disease activity (SLEDAI -2K<10 versus SLEDAI -2K≥10),baseline anti double -stranded
deoxyribonucleic acid ( anti-dsDNA )status (positive; negative) ,and region in the model .  The proportions and 95% 
confidence interval (CI) will be reported. Missing data will be imputed using the nonresponder imputation (NRI)
method . 
I4V-MC-JAHHClinical Protocol Page 11
LY3009104Treatment comparisons of continuous efficacy and health outcome variables will be made using mixed -effects 
models for repeated measures (MMRM) model with treatment, baseline score, baseline disease activity (SLEDAI -
2K<10 versus SLEDAI -2K ≥10), baseline anti-dsDNA status (positive; negative), region, visit, and the interaction 
of treatment -by-visit as fixed factors .  An unstructured covariance matrix will be used to model the within -patient 
variance -covariance errors .  Type III sums of squares for the least squares (LS) means will be used for the statistical 
comparison; the 95% CIwill also be reported .  Treatment group comparisons with placebo at Week 24 and other 
visits will be tested.
Fisher exact test will be used for all adverse events (AE s), baseline , discontinuation, and other categorical safety 
data. Continuous vital signs andlaboratory values will be analyzed by an analy sis of covariance (ANCOVA )with 
treatment and baseline value sin the model.  Other continuous safety variables will be analyzed by t -tests, unless 
otherwise stated.
I4V-MC-JAHHClinical Protocol Page 12
LY30091042.Introduction
2.1. Background
Systemic lupus ery thematosus (SLE) i s achronic, debilitat ing autoimmune disease that is 
characterized by  the presence of autor eactive B cells and elevated levels of autoantibodies, which 
directly damage the body’s cells and tissues.  SLE can affect mult iple organ sy stems 
simultaneously  or sequent ially, and f ollows an unpredi ctable clinical course where periods of 
relatively stabl e disease are fo llowed by  flares and/or peri ods of  active disease that can 
ultimately lead to irreversible damage to tissues and organ systems.
SLE is predominately a disease of wom en (~9:1, fem ale to m ale), often beginning in ado lescence 
or early adult hood.  It affects approximately 1in 1000 people in the United States ( US)and is 
more commo n in African-Americans, with as m any as 1 in 330 African -American wo men 
afflicted with S LE (Lim et al. 2014 ;Somers et al . 2014 ).  Addit ionally , SLE appears to be more 
severe in African -Americans, Asian -Americans ,and Lat inos compared to Caucasians (Pons -
Estel  et al . 2004 ).
Clinically, SLE presents with varying signs and sy mptom s, including arthralgia/arthrit is, skin 
rash, alopecia, pleurit is, pericardit is, nephrit is, vasculit is, stroke, seizure, thrombocy topenia, 
anemia, photosensit ivity, and the presence of autoant ibodies directed to nuclear ant igens .  Skin 
and jo int disease are the m ost frequent features at diagnosis.  Age, USA African race/ethnicit y, 
Systemic Lupus Ery thematosus Di sease Act ivity Index 2000 ( SLEDAI -2K) score, steroid use ,
and hypertensio n were associated with transit ion from no dam age to dam age, and increase(s) in 
preexist ing damage (Bruce et al. 2015 ).  Over 60% of pat ients with SLE will develop clinically 
detectable organ damage within 2 to 7 y ears of di agnosis, as measured by  the Sy stemic Lupus 
Erythematosus Internati onal Collaborati ng Clinics (SLICC)/ American Co llege of Rheumatology
(ACR )damage index (Cooper et al . 2007).
Improvem ents in earlier diagnosis, treatment regimens ,and medical care over the past several 
decades have reduced mortalit y in SLE; however, patients continue to experience premature 
death, with cardio vascular d isease being the leading cause.  A recent meta -analysis of published 
data invo
lving over 27,000 patients with SLE observed a 3- fold increase in risk of death in 
patients wi th SLE com pared to the general populatio n (Yurkovi ch et al . 2014 ).  Thus, there 
remains substant ial unmet medical need for individuals who suffer from SLE.
Standard of care for SLE includes corticosteroids, nonsteroidal ant i-inflammatory drugs 
(NSAIDs ), antimalarial agents, immunosuppressive agents ,and cy totoxi c agents ;however, there 
are relat ively few drugs approved for treatment of SLE.   For example, in the US, approved 
therapi es for SLE include aspirin, ant imalarials, corti costeroi ds, and belimumab.  In general, 
treatm ent regimens are similar around the world and are tailored to the severit y of disease. Mild 
disease is often treated with low -dose corti costeroi ds, NSAIDs, and antimalarials; while serious, 
organ -threatening o r life -threatening disease is ty pically treated with high -dose corti costeroi ds 
and immunosuppressive agents .  In addi tion to their di rect impact on disease, 
immunosuppressive agents are also utilized as corticosteroi d sparing agents to reduce chronic 
exposure to corticosteroids.
I4V-MC-JAHHClinical Protocol Page 13
LY3009104The current standard of care (SoC) therapi es have broad effects on immune and inflammatory  
pathways and have be en associ ated wi th short -term and l ong-term morbidi ty.  For example, 
long-term use of corti costeroi ds is associ ated wi th cataracts, osteoporosis, avascular necrosis, 
increased infect ion, hyperglycemia, and weight gain, while cyclophosphamide increases the risk 
of prem ature ovari an failure, serious infect ion
,and cancer.
Although recent improvements in treatment regimens and medical care have reduced mortalit y 
and morbidit y, many patients still have incom pletely  controlled disease and progress to end- stage 
organ invo lvement .  In addit ion, the disease increases mortalit y and negat ively impacts healt h-
related quali ty of life.  New treatm ent opti ons with an acceptable safet y profile thatreduce 
disease act ivity, reduce flares, del ay organ damage , and reduce the requirement for 
corticosteroi ds and cy totoxic agents are urgently needed for patients with SLE.
Accordingly , pharmacol ogic intervent ions that target specific pathways associated with the 
pathol ogy ofSLE m ay provi de novel  therapeut ic approaches to disease m anagement.  One of the 
signaling pathways implicated in SLE disease activit y is the t ype I interferon (IFN) signaling 
pathway .  Up -regulation of genes associated with the act ivation of ty pe IIFN signaling, referred 
to as a type IIFN signatur e, is seen in approximately  70% of  patients with SLE ( Bauer et al .
2006; Hi ggs et al . 2011).   N ot all autoimmune diseases are associated with a pronounce d type I
IFN signature ;for example ,internal data ha vesuggested that only  approximately  15% of  the 
patients with rheumatoi d arthri tis (RA) in a Phase 2 baricitinib tri al (I4V-MC-JADA [ JADA ]) 
had a similar t ype IIFN signature.  However, in SLE, a high type IIFN signature was associated 
with increased disease severit y as measured by SLEDAI score , increased anti doubl e-stranded 
deoxy ribonucleic acid (anti-dsDNA )levels, decrease dcomplement l evels ,and increased risk of 
severe flares (Bauer et al . 2009; Statistics - Devel opment/Di scovery , Eli Lilly and Com pany , 
2015).   Mult iple studi es have dem onstrated that pati ents wi th SLE have a pronounced IFN 
signature .  This observation has been confirmed using microarray  analyses from the tabalumab 
P
hase 3 SLE studies in which approximately two- thirds of pat ients had an elevated IFN signature
(Chaussabel et al . 2008 ;Berthier et al . 2012; Lauwery s et al . 2013 ).  Additionally, monocytes 
from patients with SLE dem onstrated an IFN -α2a imprint that included the upregulat ion of 
several signal transducer and activator of transcriptio n (STAT )proteins ( Smiljanovic et al .
2012).  These studies and others have provided a scient ific rationale for targeting the type IIFN 
signature as a therapeuti c opti on for SLE (Mathi an et al .
2015) .  Indeed ,this si gnature i s 
associ ated wi th a varie ty of chem okines that provide a basis for further lymphoid and myeloid 
cell infiltration into target organs (Gonzalez -Navajas et al. 
2012) .  While approaches targeting 
specific t ype IIFNs , primarily  alpha ,have not been successful ,these approaches fail to target all 
type IIFNs ,including beta,and the invo lvement of other cy tokines including IL- 6, type IIIFN, 
andothers that signal through the Janus kinase/ JAK/STAT pathways (Kirou and Gkrouzm an
2013).   Therefore ,treatm ent of SLE wi th baricitinib or other JAK inhibitors is an area of intense 
interest.
Baricitinib (also previously known as LY3009104 and INCB028050) is a potent and select ive 
small mo lecule inhibitor of JAK1 and JAK2 enzymes that i s current ly under development for the 
I4V-MC-JAHHClinical Protocol Page 14
LY3009104treatm ent of inflammatory  condi tions such as RA, diabetic kidney disease, psoriasis, and atopic 
derm atitis.
Through 10 August 2015, approximat ely 4300 subjects have received baricit inib, including 
healt hy subjects, and patients with RA, psori asis, diabet ic kidney disease, rare auto -inflammatory 
syndro mes, wi th various degrees of renal impairment, and with hepat ic dysfunct ion.  Bari citinib 
has be en administered as single doses ranging from 1 -to 40 -mg and as repeat oral doses ranging 
from 2-to 20 -mg to healthy subjects. Baricit inib has also been administered to patients with RA 
at doses up to 15
-mg daily for 4 weeks, 10 -mg daily for 24 weeks, 8 -mg daily for 76 weeks , and 
lowerdoses up to 4-mgdaily forup to approximate ly5 years.  
2.2. Study Rationale
Baricitinib is an orally available, select ive JAK inhibitor with excellent potency and select ivity 
for JAK1 and JAK2 and less potency  for JAK3 or Tyrosine kinase 2 ( TYK2 ;Fridman et al. 
2010).  Thi s activity profile suggests that baricit inib may  inhibi t cytokines implicated in SLE 
such as type I IFN (JAK1/TYK2) ,type II IFN-,IL-
6 (JAK1/JAK2/TYK2) ,and IL -23 
(JAK2/TYK2) as well as other cy tokines that m ay have a role in SLE, including granulocy te-
macrophage co lony stimulating factor (JAK2/JAK2) and IL -12(JAK2/TYK2) .  The potential 
impact of baricit inib on the IFN pathway  is highly rel evant to SLE, as clinical and preclinical 
studi es have established that this pathway  is involved in the pathogenesis of SLE.  Evidence that 
baricit inib will down -modulate this signature has been seen at the messenger ribonucleic acid 
(mRN A)level through analysis o f samples from patients treated with baricit inib in the psoriasis 
and RA programs and at the protein level in the diabet ic nephropathy  (DN) program .  Decreases 
in circulat ing levels of chemokines associated with this signature have been seen at the protein 
level in DN ( Brosi uset al. 2015 ;Tuttl e et al . 2015) and in evaluat ing type IIFN transcripts in the 
small subset of RA patients that were characterized in a Phase 2 study  as having an elevated ty pe 
IIFN signature ( Statisti cs-Devel opment/Di scovery, Eli Lilly and Company , 2015 ).  Studies 
perform ed by  the Gol dbach -Mansky  group at the Nati onal Inst itutes of Healt h (NIH)in patients 
with chroni c atypical neutrophilic dermatosis wit h lipody strophy  and elevated temperatures 
(CANDL E)have shown that treatment with baricit inib resul ted in decrease dIFN signature , and 
this reduct ion in IFN signature was consistent with an improvement in clinical symptoms
(Montealegre et al. 2015 ).  There are current investigat ions underway to decrease the IFN 
signature through the use of a monoclonal ant ibody ( anifrol umab) that target sthe type IIFN 
receptor .  While targeting the IFN signature in this manner has shown to be effect ive in SLE 
(Furie et al . 2015), i t may not be suffic ient.  Data from the tabalumab Phase 3 SLE studies
demonstrated up -regulat ion of IL -6 related genes , IL-2 receptor, IL -12, and oncostatin M , 
all of 
which signal through the JAK/STAT pathways and would not be anticipated to be direct ly 
modulated by  therapeut ic strategies which only target the IFN pathway.  Therefore, baricit inib 
may prove to be an effective treatment as it targets mult iple cy tokines that have been linked to 
SLE whose expression is dependent on JAK signaling. 
Clinical studies have established that baricit inib is effect ive in treati ngautoimmune/
autoinflammatory  diseases invo lving the j oints, skin ,and kidney s.  Bari citinib was effect ive at 
reducing swo llen and tender jo ints in patients with RA(JADA [Phase 2], and I4V -MC-JADW 
I4V-MC-JAHHClinical Protocol Page 15
LY3009104and I4V -MC-JADX [JADW and JADX, Phase 3] ), was effective at reducing disease severit y in 
patients wi th moderate to severe plaque psoriasis (Menter et al. 2014 ), and was effect ive at 
reducing urinary  albumin -to-creatinine ratio (UACR )in pat ients wi th diabeti c kidney disease 
(Tuttl e et al . 2015 ).  The mechanism of act ion, combined with demo nstrati on of  clinical  benefi t 
in inflammatory diseases invo lving jo ints, skin ,and kidneys, provides a com pelling rationale for 
evaluat ing baricit inib in SLE .
2.3. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) ,
and reasonably ant icipated adverse events (AEs) of baricit inib are to be found in the 
Invest igator’s Brochure (IB).  
I4V-MC-JAHHClinical Protocol Page 16
LY30091043.Objectives and Endpoints
Table JAHH .1shows the object ives and endpo ints of the study .
Table JAHH .1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the effect of baricitinib 4-mgdaily  (QD) or
2-mg QDcompared to placebo on remissio n of SLE 
arthritis and/or rash in patients with SLE receiving 
concomitant standard therapy over 24 weeks .C
hange in the proportion of patients who achieve 
remission of arthritis and/or rash as defined by the 
SLEDAI -2Kat Week 24 compared to baseline.
Secondary
To evaluate the effect of baricitinib 4-mg QDor2-mg 
QDcompared to placebo on overall SLE disease activity 
in patients with SLE receiving concomitant standard 
therapy  over 24 weeks.Change in the proportion of patients achieving SLE 
Responder Index 4 (SRI-4)response at Week 24 
compared to baseline.  SRI -4 response is defined as: 
oReduction of ≥4 points from baseline in 
SLEDAI -2Kscore; 
oNo new British Isles Lupus Assessment Group 
(BILAG )A or no mo re than 1 new BILAG B 
disease activity scores; and
oNo worsening (defined as an increase of 
≥0.3 points [10 mm] f rom baseline) in the 
Physician ’sGlobal Assessment of Disease 
Activity .
Change in the proportion of patients achieving a 
reductio n of ≥4 points from baseline in SLEDAI -2K 
score at Week 24 compared to baseline.
Change in SLEDAI -2K total score at Week 24 
compared to baseline.
To evaluate the effect of baricitinib 4-mg QDor2-mg 
QDcompared to placebo on thePatient ’s Global 
Assessment of Disease Activity  in patients with SLE 
receiving concomitant standard therapy over 24 weeks.Change in the Patient’s Global Assessment of 
Disease Activity  at Week 24 compared to baseline.
To characterize the pharmacokinetics (PK) of baricitinib 
4-mg QDor2-mg QDin patients with SLE receiving 
concomitant standard therapy over 24 weeks.Plasma baricitinib concentrations will be analyzed 
using a population PK (popPK) approach .
Exploratory
To evaluate the effect of baricitinib 4-mg QDor2-mg 
QDcompared to placebo on SLE arthritis and 
mucocutaneous disease activity in patients with SLE 
receiving concomitant standard therapy over 24 weeks.Continuous and categorical endpoints based on joint 
counts
Continuous and categorical endpoints based on the 
Cutaneous Lupus Erythematosus Disease Area and 
Severity  Index (CLASI ).
To evaluate the effect of baricitinib 4-mgQDor2-mg
QDcompared to placebo on overall SLE disease activity 
in patients with SLE receiving concomitant standard 
therapy  over 24 weeks.Time to and proportion of patients e xperiencing first 
flare (any severity), first mild/moderate flare, and 
first severe flare d efined by the SLEDAI Flare Index
(SFI) .
Change in SLICC/ACR Damage index score at Week 
24 compared to baseline .
I4V-MC-JAHHClinical Protocol Page 17
LY3009104Objectives Endpoints
To evaluate the corticosteroid sparing effect of 
baricitinib 4-mg QDor2 -mgQDcompared to placebo 
in patients with SLE receiving concomitant standard 
therapy  over 24 weeks.Change in p roportio n of patients receiving 
≥10mg/day  prednisone at baseline able to reduce 
prednisone (or equivalent) dose to ≤7.5-mgfor 
12consecutive weeks between Week 12 and 
Week 24.
To evaluate the effect of baricitinib 4-mgQDor2-mg
QDcompared to placebo on serologic markers of SLE in 
patients with SLE receiving concomitant standard 
therapy  over 24 weeks.The difference in reduction of IFN signature between 
treatment groups at We ek 12 and Week 24 compared 
to baseline.
In patients with elevated anti -dsDNA at baseline, 
change in anti -dsDNA level at Week 12 and Week 
24 compared to baseline.
In patients with low C3 and C4 at baseline, c hange in 
C3 and C4 levels at Week 12 and Week 24 compared 
to baseline.
To evaluate the effect of baricitinib 4-mgQDor2-mg
QDcompared to placebo on patient -reported outcomes 
(PROs) in patients with SLE receiving concomitant 
standard therapy over 24 weeks.Change in worst pain item from the Brief Pain
Inventory (BPI) at Week 12 and 24 compared to 
baseline
Change in worst joint pain item from the BPI at 
Week 12 and 24 compared to baseline
Change in worst fatigue item from the Brief Fatigue 
Inventory (BFI) at Week 12 and 24 compared to 
baseline
Change in mental component score (MCS), physical 
component s core (PCS) ,and domain scores in the 
Short -Form 36 -item health survey version 2 ( SF-
36v2 )acute at Week 12 and 24 compared to baseline .
To explore dose/ exposure response r elationships with 
key efficacy (such as SLEDAI -2K) and safety (such as 
hematologic parameters) endpoints of interest.The relationship between baricitinib PK and key  
efficacy and safety endpoints will be characterized 
using popPK /pharmacodynamics ( popPK/PD )
modeling .
I4V-MC-JAHHClinical Protocol Page 18
LY30091044.Study  Design
4.1. Overview of Study Design
Study  I4V-MC-JAHH (JAHH) is a Phase 2 ,multicenter, randomized, double -blind, placebo -
controlled, parallel -group, outpati ent, 24 -week study  evaluat ing the efficacy and safet y of 
baricit inib 4-mgand 2-mgin pat ients with SLE receiving standard therapy .
Approximately  300 patients will be rando mized 1:1:1 to receive baricit inib 4-mgdaily , 
baricit inib 2-mgdaily ,or placebo ( 100patients per treatm ent group) .  Patients will be stratified at 
rando mizat ion according to disease activit y (SLEDAI -2K<10; SLEDAI -2K≥10) , anti-dsDNA  
status (posit ive; negat ive), and region ( defined in the stati stical analysis plan [ SAP]).
The study  consists of 3 perio ds:
Screening Period :  Patients meet ing entry criteria begin the 3 -to 42 -day screening 
periodby signing the inform ed consent form(ICF) .  Patients will be screened for study  
enrollment eligibilit y at Vi sit 1, and eligible patients will be randomized at Visit 2
(Week 0).
Double -Blinded Treatment Period :  Randomized patients begin the 24 -week doubl e -
blind, pl acebo -controlled treatm ent peri od at Visit 2 (W eek 0) and administer 
investigat ional product daily th rough Visit 9 (W eek 24) .
All patients will continue on stable background standard therapy consist ing o f 
corticosteroi ds, NSAIDs (for which the NSAID use is intended for treatment of signs and 
symptoms of SLE) , a single antimalarial (such as hydroxychloroquine or chloroquine), 
and/or a single immuno suppressant (such as methotrexate [MTX] , azathioprine, or 
mycopheno late).  NSAID, antimalarial, and immunosuppressant dose sshoul d rem ain 
stable throughout the Doubl e-Blinded Treatment Period.  Decreases in corticosteroid 
dose, as well as subsequent increa ses to l ess than or equal to the baseline dose will be 
permitted between W eek 0 and W eek 16.  No changes in corticosteroid dose (increases or 
decreases) will be permitted between W eek 16 and W eek 24.  Further details regarding 
concomitant therapy  are in Se ction 6.8.
Initiation or increase in dose of NSAIDs (for whi ch the NSAID use is intended for 
treatm ent of signs and symptoms of SLE) , corti costeroi ds (above the baseline dose 
through W eek 16, or any  increase after W eek 16), ant imalarials, and/or 
immunosuppressants is not permitted after randomizat ion. After randomizat ion, pati ents 
requi ring the abovement ioned init iation or increase in dose of SLE SoC medications , as 
well as those meet ing discont inuat ion criteria, will be discont inued fro m invest igational 
product and complete the study  procedures for an early terminat ion visit (ETV) .
Follow -Up Period :Patients who complete the study through Visit 9 (Week 24), as well 
asthose who di scont inue study  treatm ent early , will  have a post -treatm ent follow-up visit 
(Visit 801) approximately 4 weeks after the last dose of invest igational product .
I4V-MC-JAHHClinical Protocol Page 19
LY3009104Figure JAHH .1illustrates the study design.   The 3 dosing regimens are described in Sect ion 6.1.  
As thi s is a doubl e-blind study , the blinding procedure described in Sect ion 6.3will be followed.
Abbreviations:  n = number of patient per treatment group; QD = daily ; V = visit; W = week.
aFor those patients with a purified protein derivative ( PPD)placed at Visit 1, Visit 1a must occur 48 to 72 hours 
post-Visit 1 for PPD to be read.  
bAllpatient s should return fora post-treatment follow -up visit (V801) 4 weeks after the last dose of 
investigational product.
Figure JAHH .
1. Illustration of stud y design for Clinical Protocol I4V-MC-JAHH .
4.2. End of Trial Definition
End of the t rial is the date of the l ast visit ,last scheduled procedure shown in the Schedule of 
Activities(Appendix 2 ), or date of di scont inued participation for the l ast pati ent.
4.3. Scientific Rationale for Study Design
The scient ific rat ionale for the primary endpoint of this study is based on analyse s from2 large 
tabal umab SLE Phase 3 trials witha similar patient populat ioninvolving over 2200 patients 
(Isenberg et al. 2015; Merrill et al. 2015 ).  The p rimary endpo int in these trials was SRI-5
.  The 
goal of theseanalyses was to characterize the clinical symptom smost responsible for achieving 
responder status with SRI-5, and then use thi s info rmation to design a moreefficient trial wit h 
clinically relevant endpoints.
To achi eve SRI -5, one needs improvement inSLEDAI, wi th no worsening inBILAG or 
Physician’s Global Assessment of Disease Activit y.  In the Phase 3 trials, BILAG and 
Physician’s Global Assessment of Dise ase Activit ycontributed minimal informat ion to SRI -5, as 
fewer than 1% of patients achieved a ≥5-point reducti on 
in SLEDAI score , but failed the 
endpo int due to worsening of BILAG or Physician’s Glo bal Assessment of Disease Act ivity.  
These data provided the rati onale to focus on SLEDAI as the primary  driver of clinical response.

I4V-MC-JAHHClinical Protocol Page 20
LY3009104The SLEDAI is a weighted disease act ivity index that measures presence or absence of disease in 
9 organ systems.  Disease act ivity in the mucocutaneous, musculoskeletal ,or immunologic organ 
system s was present in over 70% of patients at baseline, with over 98% of patients having 
mucocutaneous and/or musculo skeletal  disease at baseline .  In con trast, in the other 6 organ 
system s these di seases were present in ≤15% of patients.  These data provided the rationale to 
focus on m ucocutaneous and musculoskeletal disease as the primary  driver of clinical response.
The9 SLEDAI organ sy stems are com posed of specific disease symptoms.  Themusculoskeletal 
organ sy stem  consists of arthri tis and my ositis.  Arthrit is was the most prevalent symptom at 
baseline (>80% of patients) while myo sitis was rare (~1% of patients).  The mucocutaneous 
organ sy stem  includes rash, alopecia ,and mucosal ulcer .  Rash was the m ost comm on symptom  
in this organ system (~70% of patients), followed by alopecia (~55 %) and m ucosal  ulcer 
(~30%).  These data, in consultation wit h SLE experts, provided the rationale to focus on 
remission o f arthri tis and rash as the prim ary endpoint in the clinical trial.
This study is designed to allow for an efficient evaluat ion of efficacy using clinically relevant 
endpo ints, while st ill allowing examinat ion of the full range of SLE disease signs and symptoms .  
SLEDAI , 
BILAG ,and CLASI assessments will be completed at mostvisits, enabling the 
evaluat ion of the entire spectrum of SLE disease activit y in this tri al, although the primary 
endpo int is focused on arthrit is and rash .  
The observation t hat baricit inib was effect ive at reducing album inuria in pat ients with diabetic 
kidney disease is also relevant to the design of the trial (Tuttl e et al . 2015 ).  As in most SLE 
trials, pati ents wi th severe, active glo merul onephriti s are excluded.  However, there is interest in 
collect ing preliminary data on a subset of patients to determine if baricit inib has a posi tive 
impact on the symptoms of lupus nephrit is.  Thus, patients with a history  of nephrit is and current 
stable renal disease are encouraged to enroll.  
This study  will be doubl e-blinded and placebo -controlled to minimize bias .  The select ion of 
placebo as a com parator for this study  is warranted as there are few approved therapies for SLE 
and all pat ients in the study  are allo wed to receiv econcomitant SoC, including corticosteroids, 
NSAIDs, ant imalarials, and/or immunosuppressants.  
In order to minimize th e confounding effects of conco mitant m edicat ions, no increases above 
baseline are allowed for corticosteroids, immunosuppressants, NSAIDs ,or antimalarials during 
the trial.  Thisstrict con trol over corti costeroi ds and immunosup
pressants is supported by data 
from the Phase 3 SLE trials discussed above , where l ess than 20% of patients in any  group 
requi red a nincrease in predniso ne over the first 24 weeks ,and fewer than 10% required an
increase in predniso ne in the first 8 weeks.
Patients wi th intolerable or exacerbat ing disease requi ringinitiation or increase in dose sof 
corticosteroi ds, NSAIDs, antimalarials ,or immunosuppressants will be discontinued from study  
treatm ent and will be treated as nonresponders for the efficacy analyses.  
I4V-MC-JAHHClinical Protocol Page 21
LY30091044.4. Justification for Dose 
The baricit inib doses of 4-mgand 2-mgadministered orally once daily  were selected for SLE 
based on RA studi es (JADA [Phase 2
]and JADW and JADX [Phase 3] ) and a psoriasis study  
(I4V-MC-JADP, Phase 2) described in the IB .
In these studies, doses of 4- mg and 2 -mgdaily were generally  well tol erated based on the AE
profile and infrequent discont inuat ions of baricit inib dosing .  The ant icipated on -target, dose -
limit ing toxicit y is a small decline in hemoglo bin and hematocrit va lues result ing fro m the 
finding that ery thropoi etin signals via the JAK2/STAT5 signal transduct ion pathway  
(Klingmüller et al. 1997; Vera et al. 2008 ).  This decline in hemoglo bin and hematocrit has been 
seen to occur in higher -dose groups ( 8-mgdaily ) upon ini tiation of treatment and then stabili ze.
Baricitinib 4 -mg and 2 -mg daily doses have shown efficacy in RA with an acceptable safet y 
profile .  
There was no additional efficacy  associated wi th an 8 -mg dose in the Phase 2 RA study ;
thus,only 4-mgand 2-mghave been studied in the RA Phase 3 program.  The 4 -mg daily dose 
has demonstrated an earlier onset and a more consistent efficacy than 2 -mgdaily in RA stud ies. 
In psoriasis, baricit inib doses between 4- mgand 10 -mgwere associated with statist ically 
significant reducti ons in measures of disease activity , with greater efficacy at the higher doses.  
However, the 8 -mg and 10 -mg doses were associated with a hig her rate of AEs related to 
laboratory  abnorm alities (decreases in hemoglo bin, neutrophils, and lymphocytes), while the 
2-mg and 4 -mg dose groups had a pattern of AEs similar to placebo.  The 2 -mg dose did show 
numeric improvements in efficacy co mpared with placebo.  
The only pat ient factor thus far that has been identified to have a clinically relevant effect on the 
PK of baricit inib in co mpleted RA, psori asis,and DN studies is overall  renal funct ion.  Alt hough 
it is current lynot clearwhether different disease condit ions (such SLE v ersus RA) might resul t 
in different PK, aside from varying renal funct ion associated with the disease states, the 
difference, if any , is not expected to be substant ial.  It is therefore assumed that exposure at 2 -mg 
and 4 -mg in pat ients with SLE will be similar to th at in RA, psoriasis , and DN pati ents studi ed, 
after accounti ng for renal funct ion.  Thus, the highest baricit inib dose to be tested in SLE will be 
4-mg, which would be anticipated to show efficacy  together wi th an acceptable safet y profile, 
and also provide the opportunit y to cross -reference to the large safet y database from the RA 
Phase 3 program.  The lower dose of 2 -mgalso has the opportunit y to show efficacy  in SLE .  
I4V-MC-JAHHClinical Protocol Page 22
LY30091045.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
Patients are entered into the study  once they  have signed the ICF.  Patients may be assessed for 
study  entry  on the basis of readily available information (that is, informat ion that does not 
requi re inform ed consent from  the pati ent).
5.1. Inclusion Criteria
5.1.1. Entry Criteria
Patients areeligible for entry into the study  (eligible to sign the ICF ) only if they are ant icipated 
to meet all of the fo llowing entry  criteria
at screening (Visit 1):
Type of Patient and Disease Characteristics
[1] Are at l east 18 y ears of age. 
[2] Have received a clinical  diagnosis of SLE at l east 24 weeks prior to screening, meet ing 
at least 4 of the 11 Revised Criteria f or Cl assificat ion of Systemic Lupus 
Erythematosus according to the 1997 Update of the 1982 ACR (Tan et al . 1982; 
Hochberg et al . 1997) OR meeting at least 4 of the 2012 SLICC classification criteria
(Petri  et al .
2012) , including at least 1 clinical criterion and 1 immuno logic criterion. 
[3] Have history  of a posi tive antinuclear antibody (ANA )or a posi tive ant i
-dsDNA (if 
available). 
[4] Have act ive arthrit is and/or rash due to SLE.
Informed Consent
[5] Are able to read, understand, and give written info rmed consent.
5.1.2. Enrollment Criteria
Entered patients are eligible for enrollment into the study  (eligible for randomizat ion) only if 
they cont inue to meet all of the entry  criteria above , and m eet all of the following enrollment 
criteria at the time of randomization (Visi t 2):
Type of Patien t and Disease Characteristics
[6] Have a posit ive ANA (HEp -2 ANA titer ≥1:80) and/or a posit ive anti -dsDNA 
(≥30IU) as assessed by a central laboratory  at screening.
Note:  The ANA and/or anti -dsDNA m easurement may be repeated once 
within approximately 2 weeks of the ini tial value, and the value result ing from 
repeat testing may be accepted for enrollment eligibilit y if it meets the 
eligibilit y criterion.
I4V-MC-JAHHClinical Protocol Page 23
LY3009104[7] Have a SLEDAI -2K score ≥4 based on clinical symptoms (not including lab values) at 
rando mizat ion.
[8] Have active arthrit is and/or active rash as defined by the SLEDAI -2K at 
rando mizat ion.
5.2. Exclusion Criteria
5.2.1. Entry Criteria
Patients areineligible for entry  into the study  (ineligible to sign the ICF) if they are anti cipated to 
meet any  of the f ollowing entry  exclusion criteria at screening (Visit 1):
Medical Conditions
[9] Have act ive severe lupus nephrit isas defined in exclusion criterion [50] .
[10] Have act ive severe central  nervous system  (CNS )lupus as defined in exclusion 
criterion [51] .
[11] Have experienced a clinically  significant thrombotic event within 24 weeks of 
screening or are on anticoagulants and in the opinion of the invest igator are not well 
controlled.
[12] Have act ive fibro myalgia that ,in the invest igator’s opinio n, woul d make i t difficul t to 
appropria tely assess SLE activit y for the purposes of this study .
[13] Have been treated for or had an act ive occurrence of a systemic inflammatory 
condi tion other than SLE  such as, but not limited to, RA, juvenile chronic arthri tis, 
spondylo arthropathy , Crohn’s diseas e, ulcerat ive colit is, or psoriat ic arthrit is in the 
12weeks prior to screening .
a.Patients wi th secondary  Sjogren’s syndrome are not excluded.
[14] Have had any  major surgery  within 8 weeks prior to screening or will require major 
surgery  during the study  that, in the opinio n of the investigator in consultation wit h 
Lilly or i ts desi gnee, woul d pose an unacceptable risk to the patient.
[15] Have experienced any of the fo llowing wi thin 12 weeks of screening:  my ocardial  
infarction (MI) , unstable ischemic heart disease , stroke, or New York Heart 
Associ ation Stage IV heart failure.
[16] Have a history  or presence of cardio vascular, respiratory, hepat ic, gastrointestinal, 
endocrine, hematological, neuro logical, or neuropsychiatric disorders or any  other 
serious and/or unstable illness that, in the opinio n of the invest igator, could const itute 
an unacceptable risk when taking invest igational product or interfere with the 
interpretati on of  data.
[17] Are largely or wholly  incapaci tated permi tting litt le or no self -care, such as being 
bedridden or confined to wheelchair.
[18] Have an estimated glomerular filtration rate (eGFR) based on the most recent available 
serum  creat inine of <50mL/min/1.73 m2(if available).
I4V-MC-JAHHClinical Protocol Page 24
LY3009104[19] Have a history  of chronic liver disease with the most recent available aspart ate 
aminotransferase (AST) or alanine aminotransferase (ALT) > 2times the upper limit of 
norm al (>2 x ULN) or the most recent available total bilirubin 1.5 xULN (if 
available).
[20] Have a history  of lymphoproliferat ive disease; or have signs or symptoms sugg estive 
of possible lymphoproliferat ive disease, including lymphadenopathy  or spl enomegaly 
(other than primarily due to SLE); or have act ive primary  or recurrent m alignant 
disease; or have been in remission fro m clinically  significant malignancy  for <5 years.
a.Patients wi th cervical carcino ma in situ that has been resected with no evidence o f 
recurrence or metastatic disease for at least 3 y ears may  parti cipate in the study .
b.Patients wi th basal  cell or squam ous epi thelial skin cancers that have been 
completel y resected with no evidence of recurrence for at least 3 y ears may  
participate in the study .
[21] Have a current or recent (<4 weeks prior to screening) clinically serious viral, 
bacteri al, fungal , or parasi tic infecti on.
Note: For example, a recent viral upper respi ratory  tract infecti on or uncom plicated 
urinary  tract infect ion shoul d not be considered clinically serious .
[22] Have had symptomat ic herpes zoster infect ion within 12 weeks pri or to screening.
[23] Have a history  of disseminated/complicated herpes zoste r (for example , 
multidermatomal invo lvement, ophthalmic zoster, CNS involvement, or post -herpetic 
neuralgia).
[24] Inthe opinion o f the invest igator, are at an unacceptable risk for participat ing in the 
study .
[25] Have active or chronic viral infect ion fromhepati tis B virus (HBV), hepatit is C virus 
(HCV), or human immunodeficiency virus (HIV).
[26] Have had househo ld contact with a person with active tuberculosis (TB) and did not 
receive appropriate and documented prophylaxis for TB.
[27] Have evidence of active TB or have previously  had evidence of act ive TB and did not 
receive appropriate and documented treatment.
Prior/Concomitant Therapy
[28] Are current ly receiving oral corticosteroids at doses >20 -mgper day  of prednisone (or 
equivalent) or have adjusted the dose of cortico steroi ds wi thin 2 weeks of planned 
rando mizat ion.
[29] Have received topi cal corticosteroi ds, other than stable doses of class 6 (mild, such as 
desonide) or class 7 (least potent, such as hydrocortisone) , within 2 weeks of screening 
or wi thin 4 weeks of planned rando mizat ion.  
I4V-MC-JAHHClinical Protocol Page 25
LY3009104[30] Have received oral or parenteral [intravenous (IV)or intramuscular ( IM)]
corticosteroi ds at doses >40 -mgper day  of prednisone (or equivalent) within 6weeks 
of screening or wi thin 8weeks of planned rando mization , or are anti cipated to require 
parenteral  inject ion of corti costeroi ds during the study .
[31] Have had a jo int injected with intra- articular corti costeroids or hy aluronic acid wi thin 
2weeks ofscreening or wi thin 4weeks of planned randomizat ion.
[32] Have started treatment with or adjus ted the dose of NSAIDs (for which the NSAID 
use is intended for treatment of signs and symptoms of SLE) within 2 weeks of 
screening or within 4 weeks of planned rando mizatio n.
[33] Have started treatment with or adjusted the dose of an ant imalarial ( such as
hydroxychl oroquine, chl oroquine, quinacrine) within 10 weeks of screening or wi thin 
12 weeks of planned rando mizat ion.
[34] Have started treatment with or adjusted the dose of an immunosuppressant ( such as
MTX , azathioprine, mycopheno late) wi thin 10 weeks of scree ning or wi thin 12 weeks 
of planned randomizat ion.
[35] Have received cyclophosphamide (or any  other cytotoxi c agent) within 12 weeks pri or 
to screening.
[36] Have received etanercept, infliximab, certolizumab, adalimumab, golimumab ,or 
anakinra within 12weeks of screening; tocilizumab, abatacept, ustekinumab, 
rituximab, belimumab, or any  other B cell targeted therapies (approved or 
investigat ional) within 24 weeks of screening ; or any  other bi ologic therapy  within 
4weeks or 5 half -lives of screening, wh ichever is longer .
[37] Have received intravenous immunoglobulin (IVIg) within 24 weeks of screening.
[38] Have received plasmapheresis wit hin 12 weeks o f screening.
[39] Have been exposed to a live vaccine wit hin 12 weeks prior to planned randomizat ion 
or are expected t o need/receive a live vaccine during the course of the study  (with the 
exception of herpes zoster vaccinat ion).
a.All patients who have not received the herpes zoster vaccine at screening will be 
encouraged (per l ocal guidelines) to do so pri or to rando mizat ion; vaccinat ion 
must occur > 4 weeks prior to randomizat ion and start of invest igational product .  
Patients will  be excluded if they  were exposed to herpes zoster vaccinat ion within 
4 weeks of planned randomizat ion.
b.Invest igators should review th e vaccinat ion status of their patients and fo llow the 
local guidelines for vaccinat ion of those ≥18 years of age with nonlive vaccines 
intended to prevent infect ious di sease pri or to entering pati ents into the study .
Other Exclusions
[40] Are pregnant or nursin g at the time of screening.
I4V-MC-JAHHClinical Protocol Page 26
LY3009104[41] Are females of childbearing potential who do not agree to use 2 forms of highly 
effect ive birth control when engaging in sexual int ercourse with a m ale partner while 
enrolled in the study  and for at l east 4 weeks follo wing the l ast dose of invest igational 
product .
a.Females of nonchildbearing potential are defined as women 60years of age, 
wom en 40 and <60 y ears of age who have had a cessat ion of menses for at least 
12months, or wom en who are congenitally  or surgically sterile ( that is, have had 
a hysterectomy or bilateral oophorectomy  or tubal  ligat ion).
b.The fo llowing birth control methods are considered highly effective (the patient 
shoul d choose 2 to be used with their male partner):
ooral, injectable, or implanted hormonal con traceptives
ocondom  with a spermicidal foam, gel, film, cream, or suppository
oocclusive cap (di aphragm  or cervi cal/vault caps) wi th a spermicidal foam, gel, 
film, cream, or suppository
ointrauterine device
ointrauterine system (for example, progestin -releasin g coil )
ovasectomized male (with appropriate post- vasectomy documentation of the 
absence of sperm in the ejaculate)
Note:  When local guidelines concerning highly  effect ive methods of 
birth control differ fro m the above, the local guidelines must be 
followed. 
[42] Are males who do not agree to use 2 forms o f highly  effect ive birth control (see 
above) while engaging in sexual intercourse with female partners of childbearing 
potenti al while enrolled in the study  and for at l east 4 weeks following the last dose of 
investigat ional product.
[43] Have donated more than a single unit of blood within 4 weeks prior to screening or 
intend to donate blood during the course of the study .
[44] Have a history  of chronic alcoho l abuse, IV drug abuse, or other illicit drug abuse 
within th e 2 years pri or to screening.
[45] Have previously been rando mized in this study or any other study invest igating 
baricit inib.
[46] Are unable or unwilling to make themselves available for the duration of the study  
and/or are unwilling to fo llow study  restri ctions/procedures.
[47] Are current ly enrolled in, or discont inued wit hin 4 weeks prior to screening fro m any 
other clinical trial invo lving an invest igational product or nonapproved use of a drug 
or device or concurrent ly enrolled in any other ty pe of  medical research judged not to 
be scient ifically or medically co mpat ible wit h this study .
I4V-MC-JAHHClinical Protocol Page 27
LY3009104[48] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or sibling, 
whether bio logical or legally adopted.
[49] Are Lilly  or Incy te em ployees or ei ther’s designee.
5.2.2. Enrollment Criter ia
Entered patients are ineligible for enrollment into the study (ineligible for randomizat ion) and 
shoul d be discont inued fro m the study  if they  meet any  of the entry  exclusio n criteria above, or 
meet any  of the following enrollment exclusio n criteri aat the time of rando mizat ion (Vi sit 2):
Medical Conditions
[50] Have severe active lupus nephrit is, including urine protein/creat inine ratio 
>300 mg/mmo l (as an est imate of approximate proteinuria > 3g/day ) or active urinary  
sediment with red bl ood cell cast (
s), or histol ogical  evidence (if available) of diffuse
proliferat ive glomerulonephri tiswithin the 12 weeks prior to screening.   
Note:  The labmeasurement s related to l upus nephri tis may be repeated once within 
approximately  2 weeks of the init ial value s, and the value sresul ting from repeat 
testing may  be accepted for enrollment eligibilit y if theymeet the eligibilit y criterion.
[51] Have act ive severe CNS lupus including asept ic meningit is, cerebral vasculit is, 
demyelinat ing syndrome, myelopathy, acute confusiona l state, psy chosis, acute 
inflammatory  demyelinat ing polyradiculo neuropathy , mononeuropathy  
(single/mult iplex), cranial neuropathy , plexopathy , status epilept icus, or cerebellar 
ataxi a.
[52] Have symptomat ic herpes simplex at the time of rando mizat ion.
[53] Have scr eening el ectrocardi ogram  (ECG) abnorm alities that, in the opinio n of the 
investigator or the sponsor, are clinically significant and indicate an unacceptable risk 
for the patient’s participat ion in the study.
[54] Have evidence of active TB as documented by  a positive purified protein derivative 
(PPD) test ( ≥5-mm indurat ion between approximately 2 and 3 days after applicat ion, 
regardl ess of vaccinat ion history ), medical history , clinical  symptoms, and abnormal 
chest x -ray at screening.
The QuantiFERON®- TB Gol d test or T -SPOT®.TB test (as available and if 
compliant wi th local TB guidelines) may  be used instead of the PPD test.  Patients 
are excluded fro m the study  if the test i s not negative and there is clinical 
evidence of active TB.
[55] Have evidence of latent TB ( as documented by a posit ive PPD test, no clinical 
symptoms consistent with act ive TB, and a normal chest x -ray at screening, or as 
outlined below ) unless patient completes at least 4 weeks of appropriate treatment 
prior to randomizat ion and agrees to compl ete the rem ainder of treatment while in the 
trial.
I4V-MC-JAHHClinical Protocol Page 28
LY3009104If the PPD test is positive and the patient has no medical history  or chest x -ray 
findings consistent with active TB, the patient may have a Quant iFERON® -TB 
Gold test or T -SPOT®.TB test (as available and i f compliant wi th local TB 
guidelines).  If the test results are not negative, the patient will be considered to 
have latent TB (for purposes of this study ) and will be excluded.
The QuantiFERON®- TB Gol d test or T -SPOT®.TB test (as available and if 
compliant with local TB guidelines) may  be used instead of the PPD test.  If the 
test results are posit ive, the patient will be considered to have latent TB and will 
be excluded.  If the test is not negative, the test may be repeated once w ithin 
2weeks of the in itial value.  If the repeat test results are again not negative, the 
patient will be considered to have latent TB (for purposes of this study ) and will 
be excluded.
Except ions include patients with a history  of active or latent TB who have 
docum ented evidence o f appropri ate treatm ent and wi th no history  of re-exposure 
since their treatment was completed . (Such patients would not be required to 
undergo the protocol specific TB testing for PPD, Quant iFERON® -TB Gol d test 
or T-SPOT®.TB test, but would st ill require a baseline chest x- ray.)  
[56] Have a posit ive test for HBV defined as:
a.positive for hepat itis B surface ant igen (HBsAg), or
b.positive for anti-hepati tis B core antibody  (HBcAb) but negative for hepatit is B 
surface ant ibody  (HBsAb), or
c.positive for HBcAb and posit ive for hepatit is B virus deoxy ribonucleic acid 
(HBV DNA)
d.
Patients in Japan (or elsewhere if required ), are excl uded if they  are positive for 
HBsAg; or, are posit ive for HBcAb and/or HBsAb and positive for HBV DNA.
If any o f the HBtests have an indeterminate result, confirmatory  testing will  be 
perform ed by  an al ternate method.
[57] Have HCV (posit ive for anti -hepat itis C ant ibody  with confirmed presence of HCV).
[58] Have evidence of HIV infection and/or posit ive HIV ant ibodies.
Diagnostics Assessment s
[59] Have screening laboratory  test val ues, including thyroi d-stimulat ing horm one (TSH), 
outsi de the reference range for the populat ion or investigative site that, in the opinio n 
of the invest igator, pose an unacceptable risk for the patient’s participat ion in the 
study .
I4V-MC-JAHHClinical Protocol Page 29
LY3009104Patients who are receiving thy roxine as replacement therapy  may parti cipate in 
the study ,provided stable therapy  has been administered for ≥12 weeks and TSH 
is wit hin the laboratory’s reference range.  Patients who are receiving stable 
thyroxine replacement therapy  who have TSH m arginally  outsi de the l aboratory’s 
norm al reference range m ay parti cipate if the treating physician has documented 
that the thy roxine repl acement therapy  is adequate for the patient.
Laboratory  tests may be repeated once within approximately 2 weeks of the init ial 
value, and the value result ing from repeat testing may be accepted for enrollment 
eligibilit y if it meets the eligibilit y criterion.
[60] Have any of the fo llowing specific abnormalit ies on scree ning laboratory  tests:
a.ALT or AS T >2 xULN
b.total bilirubin ≥1.5 xULN
c.hemoglo bin <9 g/dL (90.0 g/L)
d.total white blood cell  (WBC) count <2500 cells/µL (<2.50x103/µL or <2.50 GI/L)
e.neutropeni a (absol ute neutrophil count [ANC] <1200 cells/µL) (<1.20x103/µL or
<1.20 GI/L)
f.lymphopenia (lymphocy te count < 750cells/µL) (<0.75x103/µL or <0. 75 GI/L)
Note :  Patients may be enro lled with a lymphocy te count <750 cells/µL but 
≥
500cells/µL (<0.50x103/µL or <0.50 GI/L) if the low lymphocy te count is 
considered by the investigator to be a resul t of the underlying SLE disease or 
concomitant medicat ions.
g.thrombocytopenia (pl atelets < 50,000 cells/µL) (<50x103/µL or <50 GI/L)
h.eGFR (
Modificat ion of Diet in Renal Disease [ MDRD ])<50 mL/min/1.73 m2.
In the case of any  of the a forementioned laboratory abnormalit ies, the tests may  be 
repeated once within approximately  2 weeks of the init ial values, and values result ing 
from repeat testing may be accepted for enrollment eligibilit y if they  meet the 
eligibilit y criterion.
Other Exc lusions
[61] Are women ≥40 and <60 years of age who have had a cessation o f menses for at least 
1 year, have a fo llicle -stimulating horm one (FSH) value <40 mIU/mL, and do not 
agree to use 2 forms of highly  effect ive methods of birth control when engaging in 
sexual intercourse wi th a male partner while enro lled in the study  and f or at l east 
4weeks following the last dose of invest igational product, unl ess they  are congeni tally 
or surgically sterile (that is, have had a hysterectomy , bilateral  oophorectomy , or tu bal 
ligation).
I4V-MC-JAHHClinical Protocol Page 30
LY30091045.3. Screen Failures
Patients who are entered into the study  but do not meet the enrollment criteria for participat ion in 
this study  (screen failure) m ay be re -screened once .The interval between screen failure and re-
screenings should be at least 4weeks.  At the time of re-screening ,the individual must sign a 
new ICF , repeat all necessary  screening procedures, and will be assigned a new ident ificat ion 
number.
5.4. Lifestyle and/or Dietary Requirements
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study or 
for 30 days fo llowing the l ast dose of investigational product.
I4V-MC-JAHHClinical Protocol Page 31
LY30091046.Treatment
6.1. Treatments Administered
This study  involves a comparison of baricit inib 4-mgand baricit inib 2-mgadministered orally 
once daily  with placebo . 
 Table JAHH .2shows the treatment regimens.
Table JAHH .2. Treatment Regimens
RegimenDose
Week 0 through Week 24
Baricitinib 4-mgQD 1 baricitinib 4-mgtablet and 1 placebo tablet matching baricitinib 2-mg
Baricitinib 2-mgQD 1 baricitinib 2-mgtablet and 1 placebo tablet matching baricitinib 4-mg
Placebo 2 placebo tablets : 1 matching baricitinib 4-mgand 1 matching baricitinib 2-mg
Abbreviations:  QD= daily .
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational product to the patient or legal 
representative 
verifying that instructions are fo llowed properly
maintaining accurate rec ords of investigational product dispensing and collect ion
at the end of the study ,returning all unused medication to Lilly, or its designee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by the site, as allowed by local law.
6.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized in a 1:1:1 ratio (baricit inib 
4-mg;baricit inib 2-mg;placebo) to doubl e -blind treatment at Visit 2(Week 0) .  Rando mizat ion 
will be stratified by disease act ivity (SLEDAI -2K<10; SLEDAI -2K≥10), anti-dsDNA  status 
(posi tive; negative) ,and region(defined in the SAP). Assignment to treatment groups will be 
determined by a co mputer -generated random sequence using an interactive web- response system 
(IWRS ).  The I WRS will be used to assign 2bottles(Bottl e A and Bottl e B), each containing 
36double -blind invest igational product tablets to each pat ient, starting at Visit 2 (Week 0), and
at each visit through Visit 8 (Week 20) .  Site personnel will confirm that they  have l ocated the 
correct bottles by entering a confirmat ion number found on the bottles into the IWRS.   Patients 
will be instructed to take 1 tablet from Bottle A and 1 tablet from Bottle B each day .  
6.2.1. Selection and Timing of Doses
The invest igational product (1 tablet from  Bottl e A and 1 tablet from Bottl e B) shoul d be taken
without regard to food and, if possible, at approximately the same time every dayto aid pat ient 
compliance .  Refer to Section 8.5,Pharmacokinetics, for specific instructions on dose timing at 
certain visits where a PK sample is drawn.
I4V-MC-JAHHClinical Protocol Page 32
LY30091046.3. Blinding
This is a double -blind study .  All study  assessments will be done by  study  personnel who are 
blinded to the patient’s treatment group.  Except in clinical circumstances where unblinding is 
requi red, the pati ents, invest igators, Lilly study team, and any personnel interact ing direct ly with 
patients or investigative sites wil l remain blinded to baricit inib and placebo assignment until 
after com pletion of the Doubl e-Blinded Treatm ent Peri od.  It i s expected that the need for 
unblinding a patient’s treatment prior to complet ion of the Doubl e-Blinded Treatm ent Peri od will  
be extr emely rare.  Every  effort shoul d be m ade to preserve the blind unless there is a compelling 
reason that knowledge of the specific treatment would alter the medical care of the patient.
Emergency  unblinding for AEs m ay be perform ed through the IWRS .  This option may  be used 
ONLY if the patient’sacute well-being requires knowledge o fthe pati ent’s treatm ent 
assignment.  All unblinding event sare recorded and reported by  the IWRS .
In case of an emergency , the invest igator has the sole responsibilit yfor determining if unblinding 
of a pati ent’s treatm ent assignment is warranted.  Patient safet y must always be the first 
consideration in making such a determinat ion.  If the invest igator decides that unblinding is 
warranted, the invest igator should make every  effort to con tact the Lilly clinical research 
physician ( CRP )or desi gnee prior to unblinding a pati ent’s treatment assignment unless this 
could delay  emergency  treatm ent of the pati ent.  If a patient’s treatment assignment is unblinded, 
Lilly must b e notified immediately .
If an invest igator, site personnel performing assessments, or patient is unblinded, patient 
discontinuat ion shoul d be considered after discussion with the sponsor .  In cases where there are 
ethical reasons to have the patient remain in the study , the invest igator must obtain specific 
approval  from theLilly CRP for the patient to continue in the study .
6.4. Packaging and Labeling
The sponsor (or its designee) will provide the follo wing invest igational products:
tablets containing 4-mgof baricitinib(Bottl e A)
tablets containing 2-mgof baricitinib(Bottl e B)
placebo tabl ets to m atch barici tinib 4-mgtablets (Bottl e A)
placebo tabl ets to m atch barici tinib 2-mgtablets (Bottl e B).
Baricitinib 4-mgand 2-mgtablets and packaging will be ident ical in appearance to the respective
placebo tablets in order to maintain the blind.
Invest igational product tablets will be provided in bottles containing 36 tablets .
Clinical trial materials will be labeled according to the country ’s regul atory  requi rements.   
6.5. Preparation/Handling/Storage
All invest igational product (used and parti ally used) will be returned to the sponsor or destroyed 
at site level  with the sponsor’s wri tten approval .  In so me cases, sites may destroy the material if, 
I4V-MC-JAHHClinical Protocol Page 33
LY3009104during the invest igative site select ion, the evaluator has verified and d ocum ented that the site has 
appropriate facilit ies and written procedures to dispose of clinical trial materials.
Follow storage and handling instructions on the investigational product packaging.
6.6. Dose Modification
Not applicable.
6.7. Treatment Compliance
Patient com pliance wi th invest igational product will be assessed at each visit during the 
treatm ent peri od (Visi t 3 through Visit 9) by counting returned tablets.  Deviat ions from the 
prescribed dosage regimen should be recorded in the electroni c case report form (eCRF ).
Apatient will be considered significant ly nonco mpliant if he or she misses more than 20% of the 
prescribed doses of invest igational product (full doses) during the study , unless the pati ent’s 
investigat ional product is wit hheld by the invest igator for safet y reasons .  Similarly, a patient 
will be considered significant ly noncom pliant if he or she i s judged by the invest igator to ha ve 
intentionally  or repeatedly  taken 20% more than the prescribed amount of medicat ion.
Patients will  be counseled by study  staff on the importance of taking the invest igational product 
as prescribed , as appropri ate.
Patients’compliance will be further defined in the SAP.
6.8. Concomitant Therapy
Patients will  maintain thei r usual medicat ion regimen for SLE and for any  other concomitant 
diseases throughout the study  unless specifically  excluded in the protocol (see Sect ion 5.2,
Exclusio n Cri teria). Patients taking these medicat ions should be on chronic stable dose s at the 
time of rando mizat ion, as specified by the Entry  Criteria (Secti on 5.2.1 ).
Concomitant SoC for SLE in this study can include corticosteroi ds, NSAIDs, a single 
antimalarial (such as chloroquine or hydroxychloroquine), and/or a single immunosuppressant 
(such as azathioprine, MTX, or mycopheno late).
Corti costeroi d dose must be ≤20- mgper day  of prednisone (or equivalent) and stable for 2 weeks
prior to randomizat ion.  Increases in corticosteroid dose are not permitted after randomization.  
Decreases in corticosteroid dose will be permitted between W eek 0 and W eek 16.  If 
corticosteroi d dose is decreased during this time period, subsequent incre ases, only to less than 
or equal to the baseline dose ,will be permitted until W eek 16.  No changes in corticosteroids 
(increases or decreases) will be permitted between W eek 16 and W eek 24.   
Patients who require 
initiation or increase in dose of corticost eroids after randomizat ion shoul d be discont inued fro m 
investigat ional product , have an ETV , and proceed to the Follow -Up Peri od of  the study .
Doses of NSAIDs (for which the NSAID use is intended for treatment of signs and symptoms of 
SLE), antimalarials, and immunosuppressants should not be adjusted during the Doubl e-Blinded 
Treatment Period.  Patients who require init iation or increase in dose of NSAIDs (for which the 
I4V-MC-JAHHClinical Protocol Page 34
LY3009104NSAID use is intended for treatment of signs and symptoms of SLE), antimalarials, or 
immunosuppressants after randomizat ion shoul d be di scont inued fro m invest igational product , 
have an ETV , and proceed to the Fo llow-Up Peri od of  the study .
Any changes to the patient’ s medicat ion must be discussed with the investigator . Patients should 
be instructed to consult the investigator or other appropriate study personnel at the site before 
taking any  new medicat ions or supplements.
Addit ional medicati ons are to be avoi ded during the study  unless required to treat an AE or for 
the treatment of an ongo ing medical problem .  If the need for concomitant medicat ion arises, 
inclusio n or continuat ion of the patient may  be at the discret ion of the investi gator af ter 
consultation wit h Lilly or its designee. Any addit ional  medicat ion, whether prescript ion or over -
the-counter , used at baseline and/or during the course of the study  must be docum ented in the 
eCRF wi th start and stop dates .
6.9. Treatment after Study Completion
6.9.1. Continued Access
Baricitinibwill not be m ade available afterconcl usion of the study .  Pati ents will be referred to 
their local treatm ent centers for continued therapy  as clinically i ndicated.
I4V-MC-JAHHClinical Protocol Page 35
LY30091047.Discontinuation Criteria
7.1. Discontinuation from Study Treatment
7.1.1. Interruption of Investigational Product
In some circumstances, it may  be necessary  to temporarily interrupt treatment as a result of AEs 
or abn ormal laboratory  values that m ay have an unclear relationship to invest igational product.  
Except in cases of emergency, it is recommended that the investigator consult with Lilly (or its 
designee) before temporarily interrupting therapy for reasons other than those defined in 
Table JAHH. 3below .Retest timing and frequency  is at the invest igator ’s discretion .
The invest igator must obtain approval from Lilly (or its designee) before restarting 
investigat ional product that was temporarily  discontinued because of an AE or abnormal 
laboratory  value.  Invest igational product must be held in the fo llowing si tuations and m ay be 
resum ed as noted i n Table JAHH. 3.
Table JAHH. 3
. Criteria for Temporary Interruption of Investigational Pr oduct
Hold investigational product if the following 
laboratory test results occur:Investigational product may b e resumed after 
approval from Lilly (or its designee) when:
WBC count <2000 cells/ µL
(<2.00x103/µL or <2.00 GI/L)WBC count 2500 cells/ µL
(≥2.50x103/µL or ≥2.50 GI/L)
ANC <1000 cells/ L
(<1.00x103/µL or <1.00 GI/L)ANC ≥1200 cells/ µL
(≥1.20x103/µL or ≥1.20 GI/L)
Lymphocy te count < 500cells/ µL
(<0.50x103/µL or <0. 50 GI/L)
Note :  IP can be continued with a lymphocyte count 
<500 cells/µL but ≥300 cells/µL (<0.30x103/µL or 
<0.30 GI/L) if the low lymphocyte count is 
considered by the investigator to be a result of the 
underlying SLE disease or concomitant medications .  
IP must be held for lymphocyte count <300 cells/ µL, 
regardless o f cause.Lymphocy te count 750cells/ µL
(≥0.75x103/µL or ≥0.75 GI/L)
Note :  If IP is held for lymphocyte count 
<300 cells/ µ
L, it may  be resumed after approval from 
Lilly  (or its designee) when the lymphocyte count is 
≥500 cells/ µL if the low lymphocyte count is 
considered by the investigator to be a result of the 
underlying SLE disease or concomitant medications .
Platelet count < 25,000/ µL
(<25x103/µL or <25 GI/L)Platelet count 50,000/ µL
(≥50x103/µL or ≥50 GI/L)
eGFR <40 mL/min/1.73 m2(from serum creatinine) eGFR 50 mL/min/1.73 m 2 
ALT or AST >5 xULN ALT and AST return to < 2 xULN, and IPis not 
considered to be the cause of enzyme elevation
Hemoglobin <8 g/dL (<80.0 g/L) Hemoglobin 9 g/dL   (≥90.0 g/L)
Symptomatic herpes zoster All skin lesions have crusted and are resolving
Severe infection that, in the opinion of the investigator, 
merits the IPbeing discontinuedResolution of infection
Abbreviations:  ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; eGFR = estimated glomerular filtration rate; IP = investigational product; ULN = upper limit 
of normal; WBC = white blood cell.
I4V-MC-JAHHClinical Protocol Page 36
LY30091047.1.2. Permanent Dis continuation of Investigation Product
Any pat ient who i s perm anently discont inued fro m invest igational product for an AE or 
abnorm al laboratory  resul t shoul d have the reason for invest igational product discont inuat ion 
reported as the AE or abnormal laboratory  value.  
Discontinuati on of  the in vestigational product for abnormal liver tests should be considered by 
the invest igator when a pat ient meets one of the fo llowing condi tions af ter consul tation wi th the 
Lilly designated medical mo nitor:
ALT or AST >8 xULN
ALT or AST >5 xULN for m ore than 2 weeks after tem porary  interruption of 
investigat ional product
ALT or AST >3 xULN and either total bilirubin level (TBL) >2 xULN or 
INR >1.5 xULN
ALT or AST >3 xULN wi th the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphatase (ALP) >3 xULN
ALP >2.5 xULN and TBL >2xULN
ALP >2.5 xULN wi th the appearance of fat igue, nausea, vo miting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5% ).
Patients shoul dbe discont inued from the invest igatio nal product in the fo llowing ci rcumstances:
WBC count <1000 cells/µL (1.00x103/µL or 1.00 GI/L)
ANC <500 cells/µL (0.50x103/µL or 0.50 GI/L)
Lymp hocyte count <200 cells/µL (0.20x103/µL or 0.20 GI/L)
Hem oglobin <6.5 g/dL (<65.0 g/L) .
For l ab values that meet permanent discont inuat ion thresho lds, investigat ional product should be 
discontinued unless, in the opinio n of the invest igator , the lab abnormalit y is due to intercurrent 
illness or another i dentified factor. After consultatio n with the Lilly -designated medical mo nitor, 
the pati ent m ay be able to conti nue receiving investigat ional product .  Lab tests may be repeated 
within 1 week to confirm whether discont inuat ion criteria have been me t.Furthermore, if 
investigat ional product is not discont inued due to intercurrent illness, the investigator must 
confirm the lab value no longer meets discont inuatio n thresholds fo llowing the resol ution of the 
intercurrent illness or other ident ified factor .
In addit ion, pati ents will  be discont inued fro m investigational product in the fo llowing 
circumstances:
Pregnancy
I4V-MC-JAHHClinical Protocol Page 37
LY3009104Malignancy  (except for successfully treated basal cell or squamous epithelial skin 
cancers)
HBV DNA above the l ower limit of quant ification (LLOQ)
Note :  If theHBV DNA result is“target detected ”(above the LLOQ ), then the 
patient shoul d be referred to a hepatology  specialist immediately. In selected 
cases, invest igators may temporarily cont inue investigat ional product in 
accordance wi th current immuno modulator m anagem ent in the setting of HBV 
DNA posit ivity.This option may  be considered in consul tation wi th Lilly  (or i ts 
designee) and evaluat ion of individual pat ient risks and benefits.  Refer to 
Section8.4.4 for addi tional instructi on on HBV DNA mo nitoring.
Some possible reasons that may  lead to perm anent di scontinuat ion include:
Enrollment in any other clinical tria l involving an investigational product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the patient should be discontinued from the study
oif the pat ient, for any  reason, requi res treatm ent with another th erapeuti c agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion
(including init iation or increase in dose of NSAIDs [for whi ch the NSAID use is 
intended for treatment of signs and symptoms o f SLE],corticosteroi ds [above th e 
baseline dose], antimalarials, and/or immunosuppressants) discont inuat ion from 
the invest igational product occurs prior to introduction of the new agent
Patient Deci sion
othe patient requests to be withdrawn fro m the study .
Patients who discont inue the in vestigational product early  will have ETV procedures performed 
as shown in the Schedule o f Activities (Appendix 2 )and proceed to the Follow -Up Per iod of the 
study .
7.1.3. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ify a pat ient who did not meet enrollment criteria and was 
inadvertent ly enro lled, a di scussio n must occur between the sponsor CRP and the invest igator to 
determine if the pat ient may  cont inue in the study .  If both agree i t is medically  appropriate to 
continue, the invest igator must obtain documented approval fro m the sponsor CRP to a llow the 
inadvertent ly enro lled pat ient to conti nue in the study  with or wi thout treatm ent wi th 
investigat ional product.
I4V-MC-JAHHClinical Protocol Page 38
LY30091047.1.4. Patients Lost to Follow -Up
Site personnel are expected to make diligent attempts to contact patients who fail to return for a 
scheduled visit or were otherwise unable to be fo llowed up by the site .  A patient will be 
considered lost to fo llow-up if he or she repeatedly fails to return for scheduled visits and is 
unable to be contacted by  the study  site.  
I4V-MC-JAHHClinical Protocol Page 39
LY30091048.Study  Assessments and Procedures
Appendix 2 lists the Schedule of Act ivities, with the study procedures and their timing (including 
tolerance limit s for timing).
Appendix 3 lists the laboratory tests that will be performed for this study.
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days of rece ipt of confi rmed test resul ts.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
8.1. Efficacy Assessments
8.1.1. Primary Efficacy Assessment Scale
8.1.1.1. SLEDAI -2K
The SLEDAI -2K is a validated global disease act ivity instrum ent that focuses on high -impact 
disease manifestations across 9 organ systems .  It includes 24 clinical and laboratory  variables 
with manifestati ons graded by  the affected organ system .  CNS :  Seizure, Psychosis, Organic 
Brain Syndro me, Visual Disturbance, Cranial Nerve Disorder, Lupus Headache, CVA; Vascular :  
Vasculit is; Musculo skeletal :  Arthri tis, My ositis; Renal :  Urinary  Casts, Hem aturia, Proteinuria, 
Pyuria; Mucocutaneous :  Rash, Alopecia, Mucosal Ulcers; Cardiovascular and Respiratory :  
Pleurisy , Pericardi tis; Immuno logic:  Low complement, Increased DNA Binding; Const itutional:  
Fever; Hematologic :  Thrombocy topenia, Leukopenia .  The primary endpo int in this study will 
assess remissio n of arthrit is and/or rash as defined by the SLEDAI -2K.
8.1.2. Secondary Efficacy and Exploratory Assessment s
8.1.2.1. SLE Responder Index -4 (SRI -4)
The SRI -4 is a composite index used to assess disease activit y in SLE .  The SLEDAI -2K 
component i s used to capture clinically  meaningful improvement in disease act ivity, while the 
BILAG and Physician’s Glo bal Assessment of Disease Act ivitycomponents ensure that the 
improvement in overall disease is not accompanied by  disease worsening in other organ sy stems.  
SRI-4 response is defined as: 
Reduction o f ≥4 points fr om baseline in SLEDAI -2K score; 
No new BILAG A or no more than 1 new BILAG B disease act ivity scores; and 
No worsening (defined as an increase of ≥0.3 points [10 mm] from baseline) in 
Physician’s Global Assessment of Disease Activit y.
8.1.2.2. Physician ’sGlobal Assessment of Disease Activity
The Physician’s Global Assessment of Disease Activit yis the physician’s assessment of the 
patient’s overall disea se act ivity due to SLE, as compared with all possible pat ientswith SLE .  
The Physician’s Global Assessment of Disease Activit yis scored using a 100 mm visual analog 
scale (VAS), where 0 mm (measured fro m the left starting point of the line) indicates no disease 
I4V-MC-JAHHClinical Protocol Page 40
LY3009104activit y and 100 mm (measured fro m the left starting point of the line) indicates the most severe 
disease act ivity possible for all  patients with SLE (or death) .  The Physician’s Glo bal 
Assessment of Disease Act ivityscore i s indicated by  making a vertical t ick mark on the line 
between 0 and 100 mm .  There are benchmarks of 0 (0 mm), 1 (33 mm), 2 (67 mm) ,and 
3(100 mm) on the line corresponding to no, mild, moderate, and severe SLE disease activit y, 
respectively .
8.1.2.3. BILAG2004
The BILAG2004 index is a validated global disease activit y index designed on the basis of the 
physician’s intention to treat ( ITT), focusing on changes in disease manifestations (not present, 
improving , same, worse, or new) occurring in the last 4 wee ks compared with the previous 
4weeks .  The instrument assesses 97 clinical signs, symptoms, and laboratory  param eters across 
9 organ system domains :  const itutional, mucocutaneous, neuropsy chiatri c, musculo skeletal , 
cardi orespi ratory , gastrointestinal, ophthalmic, renal, and hematology .  A BILAG A disease 
activit y score is severe disease activit y requiring high -dose oral  or IV corti costeroi ds, 
immuno modulators, or high -dose anticoagu lation alo ng with high -dose corti costeroi ds or 
immuno modulators .  A BILAG B disease act ivity score i s moderate disease activit y requiring 
low-dose oral  corti costeroi ds, intram uscular or intra -articular corti costeroi d inject ions, topical 
corticosteroi ds or immunomodulators, antimalarials, or symptomat ic therapy .  BILAG C 
corresponds to stable mild disease, BILAG D is inactive disease that was active previously, and 
BILAG E indicates the system was never invo lved.
8.1.2.4. 28 Tender Joint Count & 28 Swollen Joint Count
The 28 j oints to be examined and assessed as tender or not tender for tender jo int coun t and as 
swollen or not swollen for swollen jo int count include 14 jo ints on each side of  the pati ent’s 
body :  the 2 shoulders, the 2 elbows, the 2 wrists, the 10 me tacarpophalangeal jo ints, the 
2interphalangeal jo ints of the thumb, the 8 proximal interphalangeal jo ints, and the 2 knees .
8.1.2.5. Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI )
The CLASI is a validated scale used to assess cutaneous manifestations of SLE consisting o f 
2scores. The first summarizes the activit y of the disease while the second is a measure of the 
damage done by  the disease. Activity is scored on the basis o f erythema, scale/hyperkeratosis, 
mucous m embrane invo lvement, acute hair loss ,and nonscarring alopecia. Dam age i s scored in 
terms of dyspigmentation and scarring, including scarring alopecia.
8.1.2.6. SLEDAI Flare Index (SFI)
The SFI uses the SLEDAI -2Kscore, di sease act ivity scenarios, treatment changes, and 
Physician’s Global Assessment of Disease Activit yto define mild/moderate and severe flares. 
The index take s into account the abso lute change in total scores, new or worsening symptoms, 
and increases in medicat ion use or hospitalizat ion due to the disease act ivity.
8.1.2.7. SLICC/ACR Damage Index
The SLICC/ACR damage index is scored on 41 items represent ing damage to 12 organ systems .  
The index records damage occurring in pat ients with SLE regardless o f its cause and includes 
specific co morbidities associated wi th SLE that may  be due to treatment -related toxi city.
I4V-MC-JAHHClinical Protocol Page 41
LY30091048.1.3. Appropriateness of Assessments
All assessments made in this study  are standard, widely  used, and generally  recognized as 
reliable, accurate, and relevant.
8.2. Adverse Events
Invest igators are responsible for monitoring the safety of pat ients who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
Theinvest igator is responsible for the appropriate medical care of patientsduring the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate healt h care op tion, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the patient to discontinue the invest igational product before 
completing the study.  The patient should be fo llowed until the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study  is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via eCRF the occurrence and nature of 
each patient’s preexist ing condit ions, except SLE, as it is the disease under treatm ent in the 
study .  In addit ion, site personnel will record via e CRF any change in the condit ion(s) and any 
new condit ions as AEs . Investigators should record their assessment of the potential relatedness 
of each AE to protocol procedure, studied disease s tate, and /or invest igational product via eCRF.
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomit ant treatm ent or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the 
investigat ional product, study  device and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient’s investigational product is discontinued as a result of an AE, study  site pers onnel  
must report this to Lilly or its designee via eCRF , clarifying if possible, the circumstances 
leading to any  dosagemodifications, or discontinuations o f treatm ent. 
8.2.1. Serious Adverse Events
An SAE is any AE from this study  that resul ts in one of the fo llowing outcom es:
I4V-MC-JAHHClinical Protocol Page 42
LY3009104death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
considered significant by  the invest igator for any other reason:  important medical 
events that may  not resul t in death, be life -threatening, or require hospitalization 
may be considered serious, based upon appropriate medical judgment
Although all AEs after signing the ICF are recorded in the eCRF, SAE reporti ng begins after the 
patient has signed the ICF and has received investigational product.  However, if an SAE occurs 
after si gning the ICF, but prior to receiving investigational pr oduct, i t needs to be reported 
ONLY if it is considered reasonably possibly related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they  
are to be immediately fo llowed wi th official  notificati on on stu dy-specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.
Pregnancy ( during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and f etus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patientsummary eCRF has been com pleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
8.2.2. Adverse Events and Laboratory Tests of Special Interest 
(AESIs)
Adverse events of special interest ( AESIs )or laboratory  resul ts of special interest will include
severe or opportunist ic infections ;myelo suppressive events of anemia , leukopenia , neutr openia , 
lymphopenia ,and   thrombocy topeni a; thrombocy tosis; and elevat ions in ALT or AST (> 3 x
ULN) and total bilirubin (> 2 xULN) .
8.2.2.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the 
associ ated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of SUSARs.  Lilly  has procedures that will be followed for the recording 
I4V-MC-JAHHClinical Protocol Page 43
LY3009104and expedited reporting of SUSARs that are consistent with glo bal regulat ions and the associated 
detailed guidances.
8.2.2.2. Reasonably Anticipated Serious Adverse Events
In the SLE populat ion, the occurrence of renal failure/nephropathy , maj or cer ebrocardiovascular 
events (including cardiovascular —death, MI, hospitalizat ion for unstable angina, hospitalizat ion 
for heart failure, serious arrhy thmia, resuscitated sudden death, cardiogenic shock due to MI, 
coronary  revascularizat ion procedure; neurolo gic
—stroke; and peripheral vascular events), 
skeletal -related events (including osteoporosis), SLE flares, and serious infect ionsare reasonably 
anticipated due to the disease state, comorbid condit ions, and use o f concomitant m edicat ions.  
The serious ins tances of these reasonably  anticipated AEs will be reviewed in aggregate on a 
regul ar peri odic basis to eval uate any  numerical  imbalances between treatment groups in SAEs 
for reporting to the Food and Drug Administration in the US.
8.2.3. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
8.3. Treatment of Overdose
Refer to the IB.
8.4. Safety Assessments
8.4.1. Electrocardiograms
For each patient, 12-lead standard ECGs shoul d be collected locally according to the Schedule of 
Activities 
(Appendix 2 ).  Electrocardi ograms m ay be obtained at addit ional times, when deemed 
clinically necessary .
Any clinically  significant findings fro m ECGs that resul t in a di agnosis and that occur after the 
patient receives t he first dose o f the invest igational treatment s hould be reported to Lilly  or its 
designee as an AE via eCRF.
8.4.2. Vital Signs
For each patient, vital signs measurements should be conducted according to the Schedule o f 
Activities (Appendix 2 ).  
Any clinically  significant findings from vital signs measurement that result in a diagnosis and 
that occur af ter the pati ent receives the first dose of investigation product should be reported to 
Lilly or i ts desi gnee as an AE via eCRF.
I4V-MC-JAHHClinical Protocol Page 44
LY30091048.4.3. Laboratory Tests
For each patient, laboratory  tests detailed in ( Appendix 3 ) shoul d be conducted according to the 
Schedule of Act ivities (Appendix 2 ). 
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the pati ent receives the first dose of invest igatio nal product should be reported to Lilly  or its 
designee as an AE viaeCRF .
8.4.4. Hepatitis B Virus (HBV) DNA Monitoring
HBV DNA testing will be performed in enrolled patients who tested posit ive for HBcAb at 
screening .  Patients who are HB cAb positive and HBV DNA negat ive (undetectable) at Visit 1 
will require HBV DNA monitoring every 3 mo nths and at the patient’s last visit, regardless of 
their HBsAb status. 
If the HBV DNA result is above the LLOQ , then the pat ient shoul d be referred to a hepatol ogy 
specialist immediately .  In selected cases, investigators may temporarily cont inue invest igation 
product in accordance wit h current immuno modulator management in the setting o f HBV DNA 
positivity.  
This opti on m ay be considered in consultat ion with the sponsor (or i ts desi gnee) and 
evaluat ion of individual pat ient risks and benefits.
If a single result of “target detected” is obtained (a resul t above the LLOQ ), the test shoul d be 
repeated within approximately  2 weeks.  If the repeat test result is “target not detected ,” 
monitoring may  resume according to the Schedule of Activities.
For study  sites in Japan (or el sewhere if required) , if a pat ient is HBcAb posi tive and/or HBsAb 
positive and negat ive for HBV DNA at Visit 1, HBV DNA needs to be chec ked at l east m onthly  
and at the patient’s last visit.
8.4.5. Chest X
-ray and Tuberculosis Testing 
A posteri or-anterior view chest x -ray will be obtained l ocally , unless resul ts from a chest x -ray 
obtained wit hin 6 months prior to the study  are available .  The chest x -ray will be reviewed by  
the invest igator or his/her designee to exclude patients with act ive TB infection.  In addit ion, 
patients will  be tested at screening and entry  for evidence of active or latent TB as de scribed in 
the Exclusio n Criteria (Secti on 5.2).
8.4.6. Quick Inventory of Depressive Symptomatology Self -Rated –16
(QIDS -SR 16)
The QIDS -SR16is a 16 -item, self -report instrum ent intended to assess the existence and severit y 
of symptoms of depressio n as listed in t he American Psychiatric Association ’s Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition (APA 1994). Patients are asked to consider 
each statem ent as i t relates to the way  they  have fel t for the past 7 days .  There is a 4- point scale 
for each item ranging fro m 0 to 3. The 16 items corresponding to 9 depression domains are 
summed to give a single score ranging fro m 0 to 27, wi th higher scores denoting greater 
symptom  severi ty.  The domains assessed by the instrument include :  sad m ood, conc entrati on, 
I4V-MC-JAHHClinical Protocol Page 45
LY3009104self-criticism, suicidal ideat ion, interest, energy /fatigue, sleep disturbance (init ial, middle, and 
late inso mnia or hy perso mnia), decrease/increase in appet ite/wei ght, and psy chomotor 
agitation/retardati on.  Addit ional inform ation and the QIDS -SR16questions may be found on the 
Universit y of Pittsburgh Epidemio logy Data Center web site (Inventory  of Depressive 
Symptom atology/Quick Inventory  of Depressive Symptom atology [WWW]) (Rush et al. 2003 ; 
Trivedi et al. 2004 ).
8.4.7. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
methods .
The Lilly CRP will mo nitor safet y data throughout the course of the study .  Lilly will review 
SAEs within time frames mandated by  com pany procedures .  The Lilly CRP will, as is
appropriate, consult with the funct ionally independent Global Pat ient Safet y(GPS) therapeuti c 
area physician or clinical scient ist and periodically review trends in safety  data and l aboratory  
analytes .  Any concerning trends in frequency or severit y noted by  an investi gator and/or Lilly  or 
its designee may require further evaluation.
All deaths and SAE reports will be reviewed in a blinded manner by Lilly during the c linical 
trial.  These reports will be reviewed to ensure completeness and accuracy but will not be 
unblinded to Lilly during the clinical trial .  If a death or clinical AE is deemed serious, 
unexpected, and possibly related to invest igational product, only  Lilly GPS will be unblinded for 
regul atory  reporting and safet y monitoring purposes .  These measures will preserve the integrit y 
of the data coll ected during this trial and minimize any potential for bias while providing for 
appropriate safety  monitoring.
If a study  patient experiences elevated ALT ≥3xULN, ALP ≥2xULN, or elevated TBL ≥2x
ULN, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator.  Details for 
hepat ic monitoring depend upon the severit y and persistence of observed laboratory  test 
abnorm alities.  To ensure patient safety  and com ply with regulatory  guidance, the invest igator is 
to consul t with the Lilly CRP re garding co llection of specific reco mmended clinical information 
and fo llow-up laboratory  tests (see Appendix 4 ).
8.5. Pharmacokinetics
Blood sam ples f or PK analyses will be collected from all rando mized patients in accordance wit h 
the Schedule of Activities (Appendix 2 ).  Plasma sam ples will  be assayed for baricit inib using a 
validated liquid chro matography  tandem mass spectrom etry (LC/MS/MS )method at a laboratory  
approved by Lilly or its desi gnee .
On the day of Visit 2,after com pletion of baseline assessments (including baseline laboratory  
tests as outlined in the Schedule of Act ivities) and administration of invest igational product , a 
single PK sample will be collected 15 to 30 minutes postdose .  It is i mportant that apart from this 
single PK sample, all other baseline laboratory  samples are taken PREdose.
I4V-MC-JAHHClinical Protocol Page 46
LY3009104On the day  of Visi t 4and Visit 7, a single predose PK sample will be co llected foreach visit.   
Patients will  be advised not to take their invest igational product prior to visiting the clinic. To 
reduce the number of blood draws, the predose PK sample may be drawn at the same time as 
other routine labsrequi red at that visit .Patients can subsequent ly take their invest igational 
product at any time during their visit to the clinic. The patient should be instructed to take a dose 
ofinvestigational product from the new packages assigned at that visit. If a patient arrives at the 
clinic on the day  ofVisit
4 or Vi sit 7 after having taken the dose, the PK sample should be drawn 
with other routine labsrandomly at any time postdose; the inabilit y to collect predose samples 
will not be considered a protocol violation.
On the day  of Visi t 5,one PK samplewill be taken between 1 and 3 hours postdo se.  The visit 
shoul d be scheduled to accommodate this sampling.  Patients will be advised to record the exact 
time when the dose was taken at home and report it to the site personnel.  Alternat ively, p atients 
may take thei r invest igational product upon arrival to the clinic for thei r visit. To reduce the 
number of blood draws, the postdose PK sample may  be drawn at the same time as other routine 
labs required at that vi sit.  The inabilit y to collect postdose samples at the specified time will not 
be con sidered a protocol vio lation.
A single PK sample also is to be collected, if possible, from pat ients who discont inue the study
early .In the event of an SAE, up to 2 additional blood samples may be taken at the
investigator’s discret ion. If collected, th e PK sampl es shoul d be collected after the reported
event, approximately 6 hours apart and within 24 hours of the patient’s last dose.
For any  PK samples taken, the actual date and time of PK sample collection and the date and
time of last 2 doses prior to the PK sample should be recorded .  PK samples will be kept in 
storage at a laboratory  facility designated by  Lilly or its desi gnee .  Only samples from act ive 
doses will be assayed (PK samples from pat ients on placebo will not be assayed) .  PK samples 
may also be assayed for addit ional exploratory  analyses.  Bioanaly tical samples collected to 
measure investigational product concentration will be retained for a maximum o f 1 year 
following the last patient visit for the study .  
8.6. Pharmacodynamics
Plasma , serum ,and urine samples will be co llected for evaluat ion of pharmacodynamic (PD) 
markers, including, but not limited to anti -dsDNA, com plement, anti-Sm, anti-RNP, ant i-
SSA/Ro, and ant i-SSB/La .
The m arkers will not include any markers of the patient’s genet ic mak eup.  Samples will be 
collected at the times noted in the Schedule of Activit ies.
Bioanaly tical samples collected to m easure PD markers will be ident ified by the patient number 
(coded) and retained f or a m aximum  of 1year following last patient visit for the study at a 
facilit y selected by  Lilly or i ts desi gnee . 
I4V-MC-JAHHClinical Protocol Page 47
LY30091048.7. Genetics
8.7.1. Whole Blood Sample for Pharmacogenetic Research
A who le blood sample will be c ollected for pharmacogenet ic analysis as specified in the 
Schedule of Act ivities (Appendix 2 ) where l ocal regul ations allow.  
Samples will  not be u sed to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable response to baricit iniband to 
investigate genet ic variants though t to pl ay a rol e in SLE.  Assessment of variable response may  
include evaluat ion of AEs or differences in efficacy .  
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by the invest igator site personnel.
Samples will  be retaine d for a m aximum  of 15 y ears after the last patient visit for the study , or 
for a shorter peri od if local regulations and/or ethical review boards (ERBs)/invest igational 
review boards (IRBs) impose shorter time limits, at a facilit y selected by  Lilly or i tsdesignee.  
This retention period enables use of new techno logies, response to regulatory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of 
baricit inibor after baricit inibbeco me(s) commercially a vailable.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches include who le geno me or exome 
sequencing, geno me wide association studies, and candidate ge ne studi es.  Regardl ess of 
techno logy utilized genoty ping data generated will be used only for the specific research scope 
described in this sect ion.
8.8. Biomarkers 
Biomarker research is performed to addre ss questions of relevance to drug di sposi tion, target 
engagement, PD, mechanism of act ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
these que stions through measurement of bio molecul es including ribonucleic acid (RNA), 
proteins, lipids, and other cellular elements.
Serum , plasma, urine, and whole blood RNA samples for non -pharmacogenet ic bio marker 
research will be co llected at the times specifie d in the Schedule of Act ivities (Appendix 2 ) where 
local regulati ons all ow.
Samples will  be used for research on the drug target, disease process, variable response to 
baricit inib, pathways associ ated wi thSLE, IFN signature, mechanism o f action of  baricit inib, 
and/or research method or in validat ing diagnostic tools or assay (s) rel ated to SLE.
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by the invest igator site personnel. 
Samples will  be retained for a m aximum  15 years after the l ast pati ent vi sit for the study ,or for a 
shorter period if local regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
I4V-MC-JAHHClinical Protocol Page 48
LY3009104Lilly or i ts desi gnee.  This retention period enables use of new technologies, response to 
regul atory  questi ons, and invest igation of variable resp onse that m ay not be observed unt il later 
in the development of baricit inibor after baricit inibbeco mescommercially available.
8.9. Health Outcomes 
The self -reported questi onnai res will be administered prior to any  clinical  assessments according 
to the Schedule of Act ivities(Appendix 2 ) in countri es where the questionnaires have been 
transl ated int o the nat ive language of the region and linguistically validated .  These instruments 
will be captured at the site via an electronic patient -reported outcomes (ePRO) device.
8.9.1. Patient’s Global Assessment of Disease Activity
The Patient’s Gl obal Assessment of Di sease Act ivity is a single- item, pati ent reported scale 
developed for the assessment of the patient’s overall rat ing of their disease act ivitydue to SLE .  
The scale measures disease act ivity through a 5 point Likert scale ranging from 0 (“No disease 
activit y”) to 4(“Severe disease act ivity”) at its worst over the past 7 days (Felson et al. 1993; van 
Tuyl and Boers 2012 ).
8.9.2. Brief Pain Inventory (BPI)– Worst Pain Numeric Rating Scale
(NRS)
The BPI -sf modified is a 5 -item, self -administered questionnaire developed for the rapid 
assessment of pain, and provides informat ion on the intensit yof pain (the sensory  dimensi on) as 
well as the degree to which pain interfereswith function (the reactive dimensio n). The BPI -sf 
modified also asks quest ions about pain relief, pain qualit y, and the pati ent’s perception of the 
cause of pain .  The worst pain item o f the BPI -sf modified is a 1 -item, self -admini stered questi on 
developed for the rapid assessment of pain intensit y.  The worst pain item uses an 11 -point scale 
from 0 (“No pain ”) to 10 ( “Pain as bad as y ou can imagine ”) NRS . Since pain can be quite 
variable over a day , the worst pain item asks patie nts to rate their pain at its worst over the past 
7days (Cleeland 1991; Cleeland and Ryan 1994 ).
8.9.3. Brief Pain Inventory (BPI)– Worst Joint Pain NRS
The worst j oint pain item is adapted fro m the worst pain item o f the BPI -sf modified.  It i s a 
single- item, self -administered question developed for the rapid assessment of pain intensit y of 
the joints.  The worst jo int pain item uses an 11 -point scale fro m0 (“No joint pain”) to 10 ( “Joint 
pain as bad as y ou can imagine ”) NRS .  Since pain can be quite variable over a day, the worst 
joint pain i tem asks pat ients to rate their jo int pain a t its worst over the past 7 days 
(Cleeland1991 ; Cleeland and Ryan 1994 ).
8.9.4. Brief Fatigue Inventory (BFI) –Worst Fatigue NRS
The BFI is a brief pat ient-reported questionnaire for the rapid assessment of fatigue severit y and 
the impact of fat igue on daily funct ioning.  The BFI contains 10 items; however, the first item is 
not included in the overall scoring o f the scale as it asks about usual fatigue over the past week 
with the respondent answering “yes” or “no .” The remaining 9 items assess fatigue severit y 
I4V-MC-JAHHClinical Protocol Page 49
LY3009104(3items) and impact of fat igue on d aily functioning (6 i tems) .  The worst fat igue item of the BFI 
is a bri ef patient -reported question for the rapid assessment of worst fat igue severit y.  The i tem 
features a n 11- point numeric scale (0 [“No fat igue”] to 10 [“Fat igue as bad as you can 
imagine ”]) and asks pati ents to rate thei r fatigue at its worst over the past 7 days.  
The BFI is 
implemented without a user manual .  The instructions for the complet ion are embedded within 
the questionnaire, and pat ients will read the instructions before respond ing to the corresponding 
item(Mendoza et al . 1999 ; Wolfe 2004 ).
8.9.5. Short -Form 36 -item Health Survey v2 (SF -36)
The SF -36v2 Acute m easure i s a subject ive, generic, health -related quali ty of life instrum ent that 
is pat ient-reported and consists of 36 questions covering 8 healt h dom ains:  physical functioning, 
bodily pain, rol e limi tations due to phy sical problems, rol e limi tations due to em otional 
probl ems, general healt h perceptions, mental health, social funct ion, and vitalit y.  Each do main is 
scored by  summing the individual items and transforming the scores i nto a 0 to 100 scale wit h 
higher scores indicat ing better healt h related quali ty of life.  In addit ion, 2 summary scores, the 
PCS and the MCS, will be evaluated based on the 8 SF -36v2 Acute domains .  The acute version 
of this instrum ent has a 1 week recall period(Brazier et al. 1992; Ware and Sherbourne 1992 ).
I4V-MC-JAHHClinical Protocol Page 50
LY30091049.Statistical Considerations and Data A nalysis
9.1. Determination of Sample Size
Approximately  300 patients will be rando mized in a 1:1:1 ratio to the baricit inib 4-mg, 2-mg, 
and pl acebo treatment groups.  With 100 patients per treatment group, this study  will have 
approximately  81% power to detect a difference between baricit inib 4-mgor 2-mgandplacebo 
of ≥20% in remission rates of rash and/or arthrit is at Week 24.  The sample size was determined 
based on the chi -square test with
2-sided ty pe I error of 5 % and 40% remissio n rate of rash 
and/or arthrit is in placebo treatment group.  The sample size calculat ion was performed using  
nQuery® Advisor 7 .0 software.
9.2. General Statistical Considerations
Statistical analys is of this study  will be the responsibilit y of Eli Lilly and Com pany .
Efficacy analyses will be conducted on the modified intent -to-treat (mITT) populat ion.  Thi s set 
includes all data fro m all rando mized pat ients receiving at least 1dose of the invest igational 
product according to the treatment the patients were assigned.
All tests of treatment effects will be conducted at a 2 -sided al pha level of 0.05, unless otherwise 
stated.
Any change to the planned data analysis methods described in the protocol will require an 
amendment ONLY if it changes a principal feature of the protocol.  Any other change to the data 
analysis methods described in the protocol, and the just ification for making the change, will be 
described in the clinical study  report (CSR) .  Addi tional exploratory  analyses of the data will be 
conducted as deemed appropriate.
The SAP will provi de analysis details.
9.2.1. General Considerations for Analyses 
In general, c ontinuous data will be summarized in terms of the mean, standard deviation, 
minimum, maximum, median, and number of observat ions.  Categorical data will be summarized 
as frequency counts and percentages.
Com parisons between the baricit inib4-mgorbaricit inib 2-mg and placebo groups will be 
perform ed for all  analyses for the Doubl e
-Blinded Treatment Peri od.  No adjust mentfor 
multiplicit y will  be done for these comparisons .
Treatment comparisons of categorical efficacy variables will be made using a logistic regress ion 
analysis with treatment, baseline disease act ivity (SLEDAI -2K<10 versus SLEDAI -2K ≥ 10), 
baseline anti-dsDNA  status (posi tive; negat ive), and region in the model .  The proporti ons and 
95% confidence interval (CI) will be reported .  Missing data will be imputed using the NRI 
method. 
Treatment comparisons of continuous efficacy and heal th outcom e variables will be made using 
mixed -effects m odels for repeated measures (MMRM) m odel with treatm ent, baseline score, 
I4V-MC-JAHHClinical Protocol Page 51
LY3009104baseline disease activit y (SLEDAI -2K<10 versus SLEDAI -2K ≥ 10), baseline anti-dsDNA  status 
(posi tive; negative), region, visit, and the interaction of treatment -by-visit as fixed factors.  An 
unstructured covariance matrix will be used to model the wi thin-patient variance -covariance 
errors .  Type III sums of squares for the least squares (LS) means will be used for the statistical 
comparison; the 95% CIwill also be reported .  Treatment group comparisons wit h placebo at 
Week 24 and other visits will be tested.
Fisher exact test will be used fo r all AE, baseline, discontinuat ion, and other categorical safet y 
data.  Continuous vital signs and laboratory  values will be analyzed by an analysis of covariance 
(ANCOVA )with treatm ent and baseline value sin the model.  Other con tinuous safet y variables
will be analyzed based on t-tests, or as otherwise stated.
9.2.2. Analysis Populations
Unless otherwise specified, the efficacy ,health outcom es, and safet yanalyses will be conducted 
on the mITTpopulat ion, defined a s all randomized pati ents who received at least one dose of 
investigat ional product , even if the patient does not receive the correct treatment, or otherwise 
does not follow the protocol .  Patients will be analyzed according to the treatment to which they 
were assigned.  Si gnificant protocol  violations will be described in the SAP.
Safety analyses for the post-treatment Follow -up Peri od will be conducted on the fo llow-up
popul ation, defined as all rando mized patients who received at least 1 dose of invest igational 
product and have entered the post -treatm ent Follo w-Up Peri od.  Pati ents will  be analyzed 
according to the dosing regimen to which they were assigned in the Treatment Period.
9.2.3. Baseline Definition
Baseline will be defined as the last available value before the first dose of investigational product
for both efficacy and safet y analyses.  In most cases, this will be the measure recorded at Week 0 
(Visit 2).  Change from  baseline will be calculated as t he visit value of interest minus the 
baseline value.  For the post -treatment Follow -up Peri od, the baseline is defined as the last 
nonmissing assessme nt on or pri or to entering the post -treatment Follow -up Peri od, that i s, on or 
prior to the Week 24 visit (Visi t 9), or the end of treatment visit (including ETV ).
9.2.4. Missing Data Imputation
The patients will be considered non responder sfor the NRI analysis if they do not meet the 
clinical response criteria (for example, remissio n of rash/arthri tis, SRI -4) at Week 24.  All 
nonresponder sat Week 24 as well as all patients who discont inue study  treatm ent at any  time 
prior to Week 24, for any reason, w ill be defined as non responder sfor the NRI analysis for all 
categori cal analyses at Week 24 .  Patients who require initiation or increase in dose of NSAIDs, 
corticosteroi ds, ant imalarials, or immunosuppressants after randomizat ion(as outlined in 
Secti on6.8,Concomitant Therapy ) will be analyzed as non responders from the day  of initiation 
or increase in medication.  Rando mized patients wit hout at least 1 postbaseline observat ion will 
also be defined as non responder sfor the NRI analysis. MMRM is the primary analysis method 
for analyzing the continuous efficacy endpo ints.  In this method no imputation is needed .  
However, a sensit ivity analysis, the placebo mult iple imputation (pMI) method will be used for 
I4V-MC-JAHHClinical Protocol Page 52
LY3009104the selected analyses o f the continuous endpo ints at Visit 9 (Week 24). The pMI assumes that 
the stati stical behavior of drug -and placebo -treated pati ents after discont inuing invest igational 
product becomes that of placebo -treated pati ents.
9.2.5. Adjustment for Multiple Comparisons
No adj ustmentfor multiple com parisons will be done.
9.2.6. Adverse Events/Laboratory Results of Special Interest
Adverse events or laboratory  resul ts of special interest include severe or opportunist ic infect ions, 
myelosuppressive events of anemia, leukopenia, neutropenia, lymphopenia, thrombocy topenia, 
thrombocy tosis; and elevat ions in ALT/AST ( ≥3xULN) and total bilirubin ( ≥2xULN).  The 
number of AESI sas well as the percentage of patients who exper ienced at least 1 AESI will be 
summarized by  treatm ent group.
9.3. Treatment Group Comparability
9.3.1. Patient Disposition
A detailed description o f patient di sposi tion by treatment will be summarized with reasons for 
discontinuat ion.
9.3.2. Patient Characteristics
Summary  tables by  treatm ent group will be generated for demographics and patient 
characterist ics at baseline ( Visit 2), for historic dia gnoses, and for preexist ing condit ions.
9.3.3. Concomitant Therapy
Concomitant therapy  will be summarized and reported for the Doubl e-Blinded Treatm ent Period.  
A listing of patients using excluded medicat ions during the period will be provided.
9.3.4. Treatment Compliance
Com pliance to therapy  will be reported for the Double -Blinded Treatm ent Peri od as described in 
Secti on 6.7.
9.4. Primary  and Secondar y Anal yses
9.4.1. Primary Analyses
The primary  endpoint is the proportion of patients who achieve remissio n of arthri tis and/or rash 
as defined by  the SLEDAI -2K at Week 24 .Either arthri tis orrash (as defined by the SLEDAI -
2K) are required to be present at baseline.  If only arthrit is is present at baseline, then arthrit is has 
to be absent at Week 24 to meet th e primary  endpoint.  If only  rash is present at baseline, then 
rash has to be absent at Week 24 to meet the primary  endpo int.  If both arthrit is and rash are 
present at baseline, then the primary  endpoint is met if eit her arthrit is, or rash, or both arthri tis 
and rash are absent at Week 24.
I4V-MC-JAHHClinical Protocol Page 53
LY3009104Treatment comparison between baricit inib dose regimens ( 4-mgor 2 - mg) and pl acebo in the 
proporti on of  patients achieving remissio n of arthritis and/or rash at Week 24 (Visit 9) will be 
analyzed using the logist ic regressio nanalysis wit h treatment andbaseline disease act ivity 
(SLEDAI -2K<10 versus SLEDAI -2K ≥ 10), baseline anti-dsDNA  status (posi tive; negat ive),and 
region in the m odel.  The proportions and 95% CIwill be reported .  Missing data will be imputed 
using the NRI m ethod.
9.4.2. Secondary Analyses 
Treatment comparison between baricit inib dose regimens ( 4-mgor 2 - mg) and pl acebo for the
change from baseline in SLEDAI -2K score at Week 24,and the change from baseline in 
patient’s gl obal assessment of di sease act ivity at Week 24will be analyzed using MMRM 
method with treatm ent, baseline disease act ivity (SLEDAI -2K<10 versus SLEDAI -2K≥10), 
baseline anti-dsDNA  status (posi tive; negat ive), region, visit, and th e interacti on of  treatment -by-
visit as fixed factors.  An unstructured covariance matrix will be used  to model the within -
patient vari ance-covariance errors. Type III sum s of squares for the LS means will be used for 
the stati stical co mpar ison; the 95% CI will also be reported. Treatment group comparisons with 
placebo at Week 24 and other visit s will be tested.
Treatment comparison between baricit inib dose regimens ( 4-mgor 2 - mg) and pl acebo for  the 
proporti on of  patients achieving a SRI-4 response andfor the proporti on of  patients achieving a
reducti on of  ≥4 points in SLEDAI -2K score at Week 24will be analyzed using the logist ic 
regression model with treatm ent, baseline disease activit y (SLEDAI -2K <10 versus SLEDAI -2K 
≥10), baseline anti-dsDNA  statu s (posit ive; negative), and region in the model .  The proporti ons 
and 95% CIwill be reported .  Missing data will be imputed using the NRI method.
9.4.3. Exploratory Analyses
Study  JAHH exploratory  analyses are summarized in Table JAHH. 4.  Details o fthe exploratory  
analyses will  be outlined in the SAP.
I4V-MC-JAHHClinical Protocol Page 54
LY3009104Table JAHH. 4. Study JAHH Exploratory A nalyses
Efficacy /Safety Measures Variable Analysis
SLEDAI -2K Change in proportion of patients who achieve remission of 
arthritis and/o r rash at Week 12Logistic Regression
28 Ten der/Swollen Joint 
CountChange in number of joints affected by SLE arthritis at 
Week 12 and Week 24 compared to baselineMMRM
Change in proportion of patients with ≥50% reduction in 
number of joints affected by SLE arthritis at Week 12 and 
Week 24 compared to baselineLogistic Regression
CLASI Activity Score Change at Week 12 and Week 24 compared to baseline MMRM
Change in proportion of patients with ≥50% reduction at 
Week 12 and Week 24 compared to baselineLogistic Regression
Physician Global Assessment 
of Disease ActivityChange at Week 12 and Week 24 compared to baseline MMRM
SLEDAI Flare Index (SFI) Proportio n of patients experiencing severe , mild/moderate ,
or any severity  flareLogistic Regression
Time to first severe , mild/moderate ,or any severity  flare Kaplan -Meier 
Product Limit 
SLICC/ACR Damage Index 
ScoreChange at Week 24 compared to baseline MMRM
Corticosteroid Sparing Change in proportion of patients receiving ≥10mg/day 
prednisone at baseline able to reduce prednisone (or 
equivalent) dose ≤7.5 mg/day for 12 consecutive weeks 
between Week 12 and Week 24Logistic Regression
Serologic Markers The difference in reduction of IFN signature between 
treatment groups at Week 12 and Week 24 compared to 
baselineMMRM
Change in anti-dsDNA level at Week 12 and Week 24 
compared to baseline in patients with elevated anti -dsDNA 
at baselineMMRM
Change in C3 and C4 levels  at Week 12 and Week 24 
compared to baseline in patients with low C3 and C4 at 
baselineMMRM
Abbreviations:  AC R = American College of Rheumatology; CLASI = Cutaneous Lupus Erythematosus Disease 
Area and Severity Index; dsDNA = double -stranded deoxyribonucleic acid; IFN = interferon; MMRM = mixed -
effects models for repeated measures; SLE = systemic lupus erythematosus; SLEDAI -2K = Systemic Lupus 
Erythematosus Disease Activity Index 2000; SLICC = Systemic Lupus Erythematosus International 
Collaborating Clinics.
Note:  Additional methods may be used for analysis as deemed appropriate.
9.5. Safety Analyses
All safet y data w ill be descript ively summarized by treatment groups and analyzed based on the 
mITT populat ion.The safet y analyses include AEs, laboratory  analy tes, QIDS -SR16, and vital
signs. The duration of dosing exposure will also be summarized.   For the Doubl e-Blinded 
Treatment period, the safet y data will be summarized and analyzed with pairwise co mpar isons 
between each baricit
inib dose andplacebo .  For the post-treatment Follow -Up Period , safet y data 
will be summarized according to the dosing regime n to whi chthey were assigned during the 
I4V-MC-JAHHClinical Protocol Page 55
LY3009104treatment period .  The categorical safet y measures will be summarized wit h incidence rates and 
analyzed by Fisher exact test . The mean change in the continuous safet y measures ofthe vital 
signs
, QIDS -SR16,physical characterist ics,andlaboratory  values will be summarized by  visits
and analyzed by  ANCOVA wi th treatm ent and baseline value sin the model . Other continuous
safet y variables will be analyzed by t -tests, unl ess otherwi se stated. Missing values w ill be 
imputed by  modified last observat ion carri ed forward ( mLOCF )for continu ous vital signs and 
QIDS -SR16safet y variables.
9.5.1. Adverse Events
Adverse events are classified based upon the Medical Dictionary for Regul atory  Activities 
(MedDRA ).  An overall summary o f AEs will be provided for the Doubl e-Blinded Treatm ent 
Dosing Period .  Fisher exact test will be used to perform treatment comparisons between each 
baricit inib group and placebo.
Treatmen t-emergent adverse events ( TEAEs )are defined as AEs that first occurred or worsened 
in severit y on or after the date of the first dose of investigational product .  The number of TEAEs 
as well as the number and percentage of patients who experienced at lea st 1 TEAE will be 
summarized using MedDRA for each system organ class (or a body  system ) and each preferred 
term by treatm ent group. For events that are gender -specific, the deno minator and computation 
of the percentage will only  include pat ients from thegiven gender. TEAEs will also be 
summarized by  relati onship to invest igational product and by severit y within each treatment 
group .  Fisher exact test will be used to perform treatment comparisons between each baricit inib 
group and placebo.
SAEs includi ng deaths, treatm ent-emergent AESI s,and AEs that lead to invest igational product
discontinuat ion will  also be summarized using MedDRA for each system organ class and each 
preferred term by  treatm ent group.  Fisher exact test will be used to perform treatment 
comparisons between each baricit inib group and placebo.
A follow-up emergent adverse event (FEAE) is defined as an event that first occurred or 
worsened in severit y after the date of the Week 24 visit (Visi t 9) or the ETV .  Follow-up 
emergent AEs (all, by  maximum  severi ty, and FEAEs possibly related to invest igational product
by th e investigator) will be summarized by  MedDRA system  organ class and preferred term.
9.5.2. Clinical Laboratory Tests
All clinical laboratory  resul ts will  be descri ptively summarized by treatment group. Individ ual 
resul ts that are outside thenorm al reference ranges will be flagged in data list ings.  Quant itative 
clinical hematology , chemistry , and urinalysis variables obtained at the baseline to postbaseline 
visits will be summarized as changes fro m baseline by treatm ent group and analyzed using 
ANCOVA with treatment and baseline value in the model.   Categorical variables, including the 
incidence of abnormal values and incidence of AESIs, will be summarized by frequency and 
percentage of patients in correspondin g categori es.  Shift tables will be presented for selected 
measures.
I4V-MC-JAHHClinical Protocol Page 56
LY30091049.5.3. Vital Signs, Physical Findings, and Other Safety Evaluation
Observed values and changes fro m baseline (predose or screening if missing) for vital signs , 
QIDS -SR16,and physical characterist ics will be descript ively summarized by treatment group 
and visit.
Change from baseline to postbaseline in vital signs , QIDS -SR16,and physical characterist ics will 
be analyzed using ANCOVA wit htreatm ent and baseline value in the model.
9.6. Pharmacokinetic/Pharmacodynamic Analyses
Sparse blood samples will be co llected at selected visit s for popul ation PK analyses. PD 
endpo ints will include both efficacy and safet y measures including, but not limited to, for 
example, SLEDAI -2K, hem oglobin, and neutrophil count. Samples for inflammatory  and 
exploratory  biomarkers will also be collected.
PK data for baricit inibwill be analyzed using a popul ation approach via nonlinear mixed effects 
modeling (NONMEM) with the NONMEM software. PopPK parameters will be examined for 
relationships wit h dose, renal funct ion, and pat ient factors including but not limited to age, 
weight, and sex .  Em pirical  Bayesian est imates of clearance will be used to calculate individual 
estimates of area under the plasma concentration -time curve (AUC).
Time -course m odels of the relationship between exposure and efficacy ( SLEDAI -2K) as well as 
safet y laboratory  measures (such as hemoglo bin and neutrophil counts) will be explored .  
Evaluat ions of covariate effects (such as age, sex, renal function, baseline values, and so on ) on 
PK/PD rel ationships may also be evaluated .  Other exploratory  analyses, such as the relationship 
between baricit inibexposure and bio markers of pharmaco logic act ivity, may be undertaken as 
deem ed appropri ate.
The rel ationship between dose/predicted concentrations and efficacy (such as SLEDAI -2K)and 
key safet y markers (such as hematological endpo ints) will be explored.
9.7. Other Analyses
9.7.1. Health Outcomes
The analyses of health outcome measures includ ethe Patient’s Gl obal Assessment of Disease 
Activity, worst pai n, worst j oint pain, worst fat igue, and SF-36.  The categorical and continuous 
healt h outcom e variables will be analyzed using logist ic and MMRM methods, respectively .  
The 
analyses will be based on the mITT populat ion, unless otherwise specified.
More detailed analy ticalmethods will be described in the SAP.
9.7.2. Subgroup Analyses .
Subgroup analysis may be conducted on the primary  endpo int and select edsecondary endpo ints. 
Subgroups to be evaluated may  include gender, age, race, disease severit y,region, explorator y 
biomarkers ,and background SoC therapy .  The definit ions for the l evels o f the subgroup 
I4V-MC-JAHHClinical Protocol Page 57
LY3009104variables and the analysis methodology  will beprovided in the SAP. Addit ional subgroup 
analyses may be performed as deemed appropri ate.
9.8. Interim Analyses
No interim analyses (IA) are planned for this study.  If an unplanned IAis deemed necessary, the 
appropriate Lilly medical director, or designee, will be consulted to determine whether it is 
necessar y to am end the protocol .Adjustments to type Ierror will be made in case an unplanned 
IA for efficacy is perfo rmed.
I4V-MC-JAHHClinical Protocol Page 58
LY300910410.Study  Governance Considerations
10.1. Regulatory and Ethical Consider ations, Including the Informed 
Consent Process
10.1.1. Informed Consent
The invest igator is responsible for ensuring:
that the patient understands the potential risks and benefits of part icipating in 
the study
that informed consent is given by each patient or lega l representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of 
investigat ional product.
answering any quest ions the pati ent m ay have througho ut the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his or her participation in the trial.
10.1.2. Ethical Review
The invest igator must give assurance that the ERB was properly const ituted and convened as 
requi red by Internat ional Conference on Harmonisation (ICH) guidelines and other applicable 
laws and regulations.
Docum entati on of  ERB approval  of the protocol and t he ICF must be provided to Lilly before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs 
must be complian t with the ICH guideline on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae.
10.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines
applicable ICH GCP Gui deline s
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party .
I4V-MC-JAHHClinical Protocol Page 59
LY300910410.1.4. Invest igator Information
Physicians with a specialt y in rheumatol ogywill participate as invest igators in this clinical trial.   
Physicians with other specialt ies and experience in treatment of patients with SLE may also 
participate as invest igators. 
10.1.5. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and cond uct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
10.1.6. Final Report Signa ture
Lilly will select a qualified investigator(s) fro m among invest igators participat ing in the design, 
conduct, and/or analysis o f the study  to serve as the CSR coordinating invest igator.  If this 
investigator(s) is unable to fulfill this funct ion, anoth er invest igator will be chosen by Lilly to 
serve as the CSR coordinating invest igator.
The CSR coordinat ing invest igator(s) will sign the final CSR for this study, indicat ing agreement 
that, to the best of his or her knowledge, the report accurately descri bes the conduct and results 
of the study .
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
10.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as ap propriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction on the protocol, the complet ion of the eCRFs, and 
study  procedures.
make periodic visit s to the study  site
be available for consultation and stay in contact with the study site personnel by 
mail, tel ephone, and/or fax
review and evaluate eCRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or i ts 
I4V-MC-JAHHClinical Protocol Page 60
LY3009104representatives, and/or regulatory  agencies at any  time.  Invest igators will be given no tice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies , and applicable ERBs with direct access to original source 
docum ents.
10.2.1. Data Capture System
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  the si te into the sponsor -provided electronic data capture system.
Electronic pat ient-reported outcome (ePRO) measures are entered into an ePRO instrument at the 
time that the information is obtained.  In these instances where there is no prior written or 
electroni c source data at the site, the ePRO instrument record will serve as the source.
If ePRO records are stored at a third party  site, investi gator si tes will  have continuous access to 
the source documents during the study  and will receive an archival copy  at the end of the study  
for retenti on.
Any data for which the ePRO instrument record will serve to collect source data will be 
ident ified and documented by each site in that site’s study file .
Data m anaged by  a central  vendor, s uch as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system.  Data will subsequent ly be transferred fro m the central  
vendor to the Lilly data wareho use.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
10.3. Study and Site Closure
10.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
10.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
I4V-MC-JAHHClinical Protocol Page 61
LY300910411.References
Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, 
Patel  DD, Gregersen PK, Behrens TW. Elevated serum levels o f interferon-regul ated 
chemokines are bio markers for active human systemic lupus erythematosus. PLoS Med.
2006; 3(12),e491:2274 -2284.
Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis -Mortari  A, 
Gregersen PK, Behrens TW, Baechler EC. In terferon-regulated chemokines as bio markers 
ofsystemic lupus ery thematosus disease activit y: a validat ion study . Arthritis Rheum.
2009;60(10):3098 –3107.
Berthi er CC, Bethunaickan R, Gonzalez -Rivera T, Nai r V, Ram anujam  M, Zhang W, Botti nger 
EP, Segerer S, Lindenmeyer M, Cohen CD, Davidson A, Kretzler M .Cross -species 
transcri ptional network analysis defines shared inflammatory  responses in murine and human 
lupus nephrit is.J Immunol .2012;189(2):988-1001.
Brazi er JE, Harper R, Jones NM, O’Cathain A, Thoma s KJ, Usherwood T, West lake L. 
Validat ing the SF -36 healt h survey  questi onnai re: new outcom e measure for primary care. 
BMJ . 1992;305(6846):160 - 164.
Brosi us FC, Tuttl e KR, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Duffin KL, Haas JV, Liu 
J, Silk ME, Macias WL, Janes JM. Baricit inib in diabet ic kidney disease: biomarker analysis 
from a Phase 2, randomized, double -blind, pl acebo -controlled study  [abstract]. In: American 
Society of Nephrol ogy Kidney Week; 2015 Nov 3 -
8; San Diego, CA. J Am Soc Nephrol .
2015;26(Suppl). Abstract TH -OR034.
Bruce IN, O’Keeffe AG, Farewell V, Hanl y JG, Manzi S, Su L, et al. Factors associ ated wi th 
damage accrual  in pat ients with systemic lupus erythematosus: results from the Systemic 
Lupus Internat ional Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis.
2015;74(9):1706-1713.
Chaussabel D, Quinn C, Shen J, Pinakeen P, Glaser C, Baldwin N, et al. A m odular analysis 
framework for blood genomics studies: application to systemic lupus ery thematosus. 
Immunity .2008;29:150 -
164.
Cleeland C. Pain assessment in cancer. In: Osoba D, ed. Effect of C ancer on Quality of Life . 
Boca Raton: CRC Press, Inc.; 1991:293- 305. 
Cleeland CS, Ry an KM. Pain assessment: global use of the Brief Pain Inventory . Ann Acad Med 
Singapore. 1994;23(2):129 -138. 
Cooper GS, Treadwell EL, St.Clair EW, Gilkeson GS, Dooley MA. Sociodem ographic 
associ ations wi th early disease damage in pat ients with systemic lupus ery thematosus.
Arthritis Rheum . 2007;57(6):993 -999.
Felson DT, Anderson JJ, Boers M, Bombardier C, Cherno ff M, Fried B, Furst D, Goldsmit h C, 
Kieszak S, Lightfoot R, Paulus H, Tugwell P, W einblatt M, Wi dmark R, Williams HJ, Wolfe 
F. The American Co llege of Rheumatology preliminary core set of disease act ivity measures 
for rheumatoi d arthri tis clinical tri als. The Co mmit tee on Outcome Measures in Rheumatoid 
Arthri tis Clin ical Tri als.Arthritis Rheum . 1993;36(6):729-740.
I4V-MC-JAHHClinical Protocol Page 62
LY3009104Fridman JS, Scherle PA, Co llins R, Burn TC, Li  Y, Li  J, et al. Selective inhibit ion of JAK1 and 
JAK2 i s efficaci ous in rodent models of arthri tis: preclinical characterizat ion of INCB028050.
J Immunol. 2010;184(9):5298 -5307.
Friedewald WT, Levy RI, Fredrickson DS. Estimatio n of the co ncentration of low -densit y 
lipoprotein cho lesterol  in plasma, wi thout use of the preparative ultracen trifuge. Clin Chem . 
1972;18(6):499 -502.
Furie R, Merrill JT, Werth VP, Khamashta M, Kalunian K, Brohawn P, Illei G, Drappa J, Wang 
L, Yoo S. Anifro lumab, an ant i-interferon al pha receptor m onocl onal antibody , in m oderate to 
severe systemic lupus ery thematosus (SLE) [abstract]. In: 2015 ACR/ARHP Annual Meet ing; 
2015 Nov 7 -11;San Francisco, CA. Arthritis Rheum. 2015;67(S10):S3865 -3866. Abstract 
number 3223.
Gonzalez -Navajas J M, Lee J, David M, Raz E. Immuno modulatory  functi ons of  type I 
interferons. Nat Rev Immunol . 2012;12(2) :125-135.
Higgs BW, Liu Z, White B, Zhu W, White WI , Morehouse C, Brohawn P, Kiener PA, Richman 
L, Forentino D, Greenberg SA, Jallal B, Yao Y. Patients with systemic lupus ery thematosus, 
myositis, rheumatoi d arthri tis and scleroderma share activation of a commo n type I interferon 
pathway . 
Ann Rheum Dis . 2011;70:2029 - 2036.
Hochb erg MC, for the Di agnosti c and Therapeut ic Criteria Committee of the American College 
of Rheumatol ogy. Updating the American College of Rheumatology  revised criteria for the 
classificat ion of systemic lupus ery thematosus [l etter]. Arthritis Rheum . 1997;40:1725.
Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan -Cox M, 
Iikuni N, Silk M, Wallace DJ. Efficacy  and safet y of subcutaneous tabalumab in pat ients with 
systemic lupus ery thematosus: resul ts from ILLUMINATE -1, a 52 -week, phase III, 
multicentre, randomised, double -blind, pl acebo -controlled study . Ann Rheum Dis. 2015 Sep 3. 
pii: annrheumdis -2015- 207653. doi : 10.1136/annrheumdis - 2015 -207653.
Kirou KA, Gkrouzman E. Ant i
-interferon alpha treatm ent in SL E. Clin Immun.
2013;148(3):303 –312.
Klingmüller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC, Lodish HF. 
Ident ification of a novel pathway important for proliferat ion and differentiation of primary 
erythroid progeni tors. Proc Natl Acad Sci USA. 1997;94(7):3016-3021 .
Lauwerys BR, Hachulla E, Spertini F, Lazaro E, Jorgensen C, Mariette X, Haelterman E, 
Grouard -Vogel G, Fanget B, Dhellin O, Vandepapeliere P, Houssiau FA. Down -regulation of 
interferon signature in systemic lupus ery thematosus patients b y active immunizat ion with 
interferon α -kinoid.Arthritis Rheum .2013;65(2):447 -456.
Lim SS, Bay
akly AR, Helmick CG, Gordon C, Easley KA, Drenkard C. The incidence and 
prevalence o f systemic lupus ery thematosus, 2002 -2004: The Georgia Lupus Registry .
Arthritis Rheum . 2014;66(2):357 -368.
Mathian A, Hie M, Cohen- Aubart F, Amoura Z. Targeting interferons in systemic lupus: current 
and future prospects. Drugs. 2015;75:835 -846.
I4V-MC-JAHHClinical Protocol Page 63
LY3009104Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL. The 
rapid assessment of fat igue severit y in cancer patients: use of the Brief Fat igue Inventory. 
Cancer . 1999;85(5):1186-1196.
Menter A, Disch D, Clemens J, Janes J, Papp K, Macias W. A Phase 2b trial of baricit inib, an 
oral JAK inhibitor, i n pat ients withmoderate -to-severe psoriasis [abstract] . In: American 
Academy  of Derm atology 72ndAnnual  Meeting; March 21 -25, 2014; Denver (CO). J Am Acad 
Dermatol . 2014;70(5(1)) .Abstract AB162 .
Merrill JT, van Vo llenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan- Cox M, Dickson C, 
Anderson PW , Lee C, Bercl az PY, Dörner T. Efficacy and safet y of subcutaneous tabalumab, 
a monocl onal antibody  to B -cell act ivating factor, in patients with systemic lupus 
erythematosus: results from ILLUMINATE- 2, a 52 -week, phase III, mult icentre, randomised, 
doubl e-blind, placebo -controlled stud y. Ann Rheum Dis. 2015 Aug 20. pii: annrheumdis -2015-
207654. doi: 10.1136/annrheumdis -
2015-207654.
Monteal egre G, Reinhardt A, Brogan P, Berkun Y, Zlotogorski A, Brown D, et al. Preliminary  
response to Janus kinase inhibit ion with baricitinib in chronic at ypical neutrophilic dermatosis 
with lipodystrophy  and elevated temperatures (CANDLE). Pediatr Rheumatol Online J.
2015;13(Suppl 1):O31.
Petri M, Orbai A -
M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al.Derivation and 
validat ion of the Sy stemic Lupus Internat ional Collaborating Clinics Classificiat ion Cri teria 
for Systemic Lupus Ery thematosus. Arthritis Rheum. 2012; 64(8):2677 - 2686.
Pons -Estel  BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, Abadi I, Caeiro F, 
Alvarellos A, Alarcon -Segov ia D. The GLADEL m ultinational Latin American Prospec tive 
Incept ion Cohort of 1,214 patients with s ystemic lupus ery thematosus ethnic and disease 
heterogeneit y among ‘‘Hispanics.’’ Medicine. 2004;83(1):1 -17.
Rush AJ, Trivedia MH, Ibrahima HM, Carmody  TJ, Arnowc B, Kleind DN, Markowitze JC, 
Ninanf PT, Kornsteing S, Manberc R, Thaseh ME, Kocsise JH, Kelleri MB. The 16- Item 
quick inventory  of depressive symptom atology (QIDS), clinician rat ing (QIDS -C), and self -
report (QIDS -SR): a psycho metric evaluat ion in patients with chronic major depression. Biol 
Psychiatry . 2003;54(5):573 -583.
Smiljano vic B, Grun JR, Bi esen R, Schul te-Wrede U, Baum grass R, Stuhlmuller B, Maslinski W, 
Hiepe F, Burm ester G -R, Radbruch A, Haupl T, Grutzkau A. The m ultifaceted balance of 
TNF -α and ty pe I/II interferon responses in SLE and RA: how monocy tes m anage the impact 
of cytokines . J Mol Med. 2012; 90:1295 -1309.
SomersEC, Marder W, Cagno li P, Lewis EE, DeGuire P, Gordon C, Helmick CG, Wang L, 
Wing JJ, Dhar P, Leisen J, Shalt is D, McCune WJ. Populat ion-based incidence and prevalence 
of systemic lupus ery thematosus . Arthritis Rheum . 2014;66(2):369-378.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, 
Winche ster RJ. The 1982 revised criteria for the classificat ion of systemic lupus ery thematosus. 
Arthritis Rheum. 1982;25(11):1271 –1277.
Trivedi MH, Rush AJ, Ibrahim HM, Carm ody TJ, Bi ggs MM, Suppes T, Cri smon ML, Shores -
Wilson K, Toprac MG, Dennehy EB, Witte B, Kashner TM. The Inventory  of Depressive 
Symptom atology, Clinician Rating (IDS -C) and Self -Report (IDS -SR), and the Quick 
I4V-MC-JAHHClinical Protocol Page 64
LY3009104Inventory  of Depressive Symptom atology, Clinician Rat ing (QIDS -C) and Self -Report (QIDS -
SR) in public sector patients with mood disord ers: a psy chometric evaluat ion.Psychol Med. 
2004;34(1):73 -82.
Tuttl e KR, Brosi us FC III, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Liu J, Silk ME, 
Cardillo TE, Duffin KL, Haas JV, Macias WL, Janes JM. Baricitinib in diabet ic kidney 
disease: results fro m a phase 2, mult icenter, randomized, double -blind, p lacebo -controlled 
study [abstract] . In: American Diabetes Associat ion 75thScient ific Sessio ns; 2015 June 5
-9; 
Boston (MA). Diabetes .2015;64( Suppl 1 A).Abstract 114 -LB.
Universit y of Pittsburgh Epidemio logy Data Center. Inventory  of Depressive Symptom atology 
(IDS)/Qui ck Inventory  of Depressive Symptom atology (QIDS). Available at: http://www.ids -
qids.org/. Accessed October 19, 2015 .
van Tuyl LHD, Boers M.Patient’s Global Assessment of Disease Act ivity: What are we 
measuring? Arthritis Rheum . 2012;64(9):2811- 2813.
Vera J, Millat T, Kolch W, Wo lkenhauer O. Dynamics o f receptor and protein transducer 
homodimerisat ion. BMC Syst Biol. 2008;2 : 92.
Ware JE, Jr, Sherbourne CD. The MOS 36 -Item Short -Form  Heal thSurvey (SF -36): I. 
Conceptual  framework and i tem select ion. Med Care . 
1992;30(6):473-483.
Wolfe F. Fat igue assessments in rheumatoid arthritis: co mparat ive performance of visual analog 
scales and longer fatig ue questi onnai res in 7760 pati ents. J Rheumatol . 2004;31(10):1896 -
1902.
Yurkovi ch M ,Vostretsova K, Chen W, Avina -Zubieta JA. Overall and c ause- specific m ortali ty 
in patients wi th systemic lupus ery thematosus: ameta -analysis of observat ional studies. 
Arthritis Care Res . 2014;66(4):608-616.
I4V-MC-JAHHClinical Protocol Page 65
LY3009104Appendix 1. Abbreviations and Definitions
Term Definition
ACR American College of Rheumatology
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medici nal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
ANA antinuclear antibody
ANC absolute neutrophil count
ANCOVA analy sis of covariance
AST aspartate aminotransferase
BFI Brief Fatigue Inventory
BPI Brief Pain Inventory
BILAG British I sles Lupus Assessment Group
blinding/masking A double -blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.
BPI Brief Pain Inventory
CI confidence interval
CLASI Cutaneous Lupus Erythematosus Disease Area and Severity Index
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
CNS central nervous system
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
I4V-MC-JAHHClinical Protocol Page 66
LY3009104CSR clinical study repo rt
dsDNA double -stranded deoxyribonucleic acid
DN diabetic nephropathy
DNA deoxyribonucleic acid
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ePRO electronic patient -reported outcome
ERB ethical review board
ETV early  termination visit
FEAE follow -up emergent adverse event
FSH follicle -stimulating hormone
GCP good clinical practice
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
IA interim analy ses
IB Investigator’s Brochure
ICF informed consent form
ICH International Conference on Harmonisation
IFN interferon
I4V-MC-JAHHClinical Protocol Page 67
LY3009104IM intramuscular
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way diffe rent from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRBs investigational review boards
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a patient (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients allocat ed to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IV intravenous
IVIg intravenous immunoglobulin
IWRS interactive web -response sy stem
JAK Janus kinase
LLN lower limit of normal
LLOQ lower limit of quantification
LS mean s least squares mean s
MCS mental component score
MedDRA Medical Dictionary for Regulatory Activities
MI myocardial infarction
mITT modified intent -to-treat 
MMRM mixed-effects models for repeated measures
mRNA messenger ribonucleic acid
MTX methotrexate
NONMEM nonline ar mixed effects modeling
NRI nonresponder imputation
NRS numeric rating scale
NSAIDs nonsteroidal anti -inflammatory drugs
I4V-MC-JAHHClinical Protocol Page 68
LY3009104PCS physical component score
PD pharmacodynamics(s)
PK pharmacokinetic (s )
pMI placebo multiple imputation
popPK/PD populatio n pharmacokinetics/pharmacodynamics
PPD purified protein derivative
QD daily
QIDS -SR16 Quick Inventory of Depressive Symptomatology Self -Rated –16
RA rheumatoid arthritis
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SF-36 Short-F orm 36 -item health survey version 2
SFI SLEDAI Flare Index
SLE systemic lupus eryth ematosus
SLEDAI -2K Systemic Lupus Erythematosus Disease Activity Index 2000
SLICC Systemic Lupus Erythematosus International Collaborating Clinics
SoC standard of care
SRI SLE Responder Index
STAT signal transducer and activator of transcription
SUSARs suspected unexpected serious adverse reactions
TB tuberculosis
TBL total bilirubin level
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and that does not necessarily have to 
have a causal relationship with this treatment.
TSH thyroid-stimulating hormone
I4V-MC-JAHHClinical Protocol Page 69
LY3009104TYK Tyrosine kinase
UACR urinary  albumin -to-creatinine ratio
ULN upper limit of normal
WBC white blood cells
I4V-MC-JAHHClinical Protocol Page 70
LY3009104Appendix 2. Schedule of A ctivities
I4V-MC-JAHHClinical Protocol Page 71
LY3009104Schedule of Activities , Protocol I4V -MC -JAHH
Screening Double -Blinded Treatment Follow -Up
Visit Number V1 V1 aaV2bV3 V4 V5 V6 V7 V8 V9 ETc,dV801d,e
Study Week -6 0 2 4 8 12 16 20 24 any28 or last dose
+ 4 weeks
Study Day-42
to -31 15 ±329± 4 57 ± 4 85 ± 4 113 ± 4 141 ± 4 169 ± 4 any197± 5 or last dose 
+ 28  ± 5 days
Procedure 
Informed consent X
Medical history X
Physical examination X
Symptom -directed physical 
examinationX X X X X X X X X X
Previous SLE therapy X X
Patient demographics X
Height X
Weight X X X X X X X X X X X
Waist circumference X X X X
Vital signs (BP, pulse, 
temperature)X X X X X X X X X X X
HabitsfX
ECGgX
Inclusion/exclusion criteria 
review for entryX
Inclusion/exclusion criteria 
review for enrollmentX
Administer TB testhX
Read PPD test if used for TB 
testingX
Chest x- rayiX
Preexisting conditions X X
Adverse events X X X X X X X X X X
I4V-MC-JAHHClinical Protocol Page 72
LY3009104Screening Double -Blinded Treatment Follow -Up
Visit Number V1 V1 aaV2bV3 V4 V5 V6 V7 V8 V9 ETc,dV801d,e
Study Week -6 0 2 4 8 12 16 20 24 any28 or last dose
+ 4 weeks
Study Day-42
to -31 15 ±329± 4 57 ± 4 85 ± 4 113 ± 4 141 ± 4 169 ± 4 any197± 5 or last dose 
+ 28  ± 5 days
Concomitant medications X X X X X X X X X X X
Randomization X
Log in IWRS X X X X X X X X X X X
Investigational product 
dispensedX X X X X X X
Investigational product returned 
and compliance assessedX X X X X X X X
Clinical Efficacy
SLEDAI -2K X X X X X X X X X X X
BILAG2004 X X X X X X X X X X
SLEDAI Flare Index (SFI) X X X X X X X X X X
SLICC X X X
CLASI X X X X X X X X X X
28-Tender and Swollen Joint 
count sX X X X X X X X X X
Physician ’sGlobal Assessment 
of Disease Activity  (VAS)X X X X X X X X X X
Patient’s Global Assessment of 
Disease Activityj X X X X X X X X X X X
BPI(Worst Pain)jX X X X X X X X X X X
BPI(Worst Joint Pain)jX X X X X X X X X X X
BFI(Worst Fatigue)jX X X X X X X X X X X
SF-36jX X X X X
QIDS -SR 16jX X X X X X X X X X X
Laboratory Tests
TSH X
I4V-MC-JAHHClinical Protocol Page 73
LY3009104Screening Double -Blinded Treatment Follow -Up
Visit Number V1 V1 aaV2bV3 V4 V5 V6 V7 V8 V9 ETc,dV801d,e
Study Week -6 0 2 4 8 12 16 20 24 any28 or last dose
+ 4 weeks
Study Day-42
to -31 15 ±329± 4 57 ± 4 85 ± 4 113 ± 4 141 ± 4 169 ± 4 any197± 5 or last dose 
+ 28  ± 5 days
HIV X
Hepatitis C antibody testing X
Hepatitis B testing (HBsAg, 
HBcAb, HBsAb)X
HBV DNAkX X X X X
Serum pregnancy testlX X
Urine pregnancy testlX X X X X X X X X X
FSHmX
Clinical chemistrynX X X X X X X X X X X
Fasting lipid paneloX X X
Hematology X X X X X X X X X X X
Iron studies (iron, TIBC, and 
ferritin)X X X
hsCRP X X X
Urinaly sis X X X X X X X X X X X
ANA X X X
anti-dsDNA X X X X X X X X X X X
Autoantibodies (anti -Sm, anti -
RNP, anti -SSA/Ro, anti -
SSB/La)X X X
Antiphospholipid antibodies X X X
Complement (C3 and C4) X X X X X X X X X X X
Immunoglobulins (IgG, IgA, 
IgM)X X X X X X
Lymphocy te subsets (T, B, NK, 
and T -cell subsets)X X X X X X
I4V-MC-JAHHClinical Protocol Page 74
LY3009104Screening Double -Blinded Treatment Follow -Up
Visit Number V1 V1 aaV2bV3 V4 V5 V6 V7 V8 V9 ETc,dV801d,e
Study Week -6 0 2 4 8 12 16 20 24 any28 or last dose
+ 4 weeks
Study Day-42
to -31 15 ±329± 4 57 ± 4 85 ± 4 113 ± 4 141 ± 4 169 ± 4 any197± 5 or last dose 
+ 28  ± 5 days
Explo ratory  storage samples 
(serum and plasma)X X X X
Explo ratory  storage samples 
(urine)X X X X
Explo ratory  storage samples 
(RNA)X X X X X
Baricitinib plasma 
concentrations (PK sample)XpXqXrXqXs
Pharmacogenetic (DNA) 
collectionX
Abbreviations :  ANA = antinuclear antibody ; BFI = Brief Fatigue Inventory; BILAG = British Isles Lupus Assessment Group; BP = blood pressure; BPI = Brief 
Pain Inventory; CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index ;dsDNA = double -stranded deoxyribonucleic acid; ECG  = 
electrocardiogram; ET = early  termination ; FSH = follicle -stimulating hormone ; HBVDNA = hepatitis B virus deoxyribonucleic acid ; HBc Ab = hepatitis B 
core antibody ; HBsAb = hepatitis B surface antibody ; HBsAg = hepatitis B surface antigen; HIV = human immunodeficiency virus; hsCRP = high-sensitivity 
C-reactive protein ; IWRS = interactive web -response sy stem; PK = pharmacokinetics; PPD = purified protein deri vative; QIDS -SR 16= Quick Inventory of 
Depressive Symptomatology Self -Rated -16; RNA = ribonucleic acid; SF-36 = Short -Form 36 -item Health Survey; SLE = systemic lupus erythematosus; 
SLEDAI -2K= Systemic Lupus Erythematosus Disease Activity Index 2000 ; SLICC = Systemic Lupus Erythematosus International Collaborating Clinics ;
TB= tuberculosis; TIBC = total iron binding capacity ; TSH = thyroid-stimulating hormone ; V = visit ; VAS = visual analog scale .
aFor those patients with a PPD placed at Visit 1, Vis it 1a must occur 48 to 72 hours post -Visit 1 for PPD to be read. PPD does not need to be read at the site, 
but must be read by a trained medical professional and results must be presented to the site at Visit 2.
bAll b aseline assessments at Visit 2 must b e performed and baseline laboratory samples must be drawn PRIOR to administration of the first dose of 
investigational product .
cThose patients who discontinue from investigational product early should complete the ETvisit and proceed to post-treatment follow -up. 
dThe ETvisit can serve as Visit 801 if it occurs at least 28 days following the last dose of investigational product.
eAll patients should return for a post-treatment follow -up visit 28 days after the last dose of investigational product . 
fInclude srecording of habits such as caffeine, alcohol, and tobacco consumption.
gECGs will be performed locally and will be locally (machine) read.
hIf the PPD test results are positive and the patient has no medical history or chest x -ray findings con sistent with active TB, the patient may have a 
QuantiFERON -TB Gold or T -SPOT.TB test (if available). If the QuantiFERON -TB Gold or T -SPOT.TB test results are not negative, the patient will be 
I4V-MC-JAHHClinical Protocol Page 75
LY3009104considered to have latent TB. If the QuantiFERON -TB Gold or T -SPOT.TB test is available and, in the judgment of the investigator, is preferred as an 
alternative to the PPD skin test for the evaluation of TB infection, it may be used instead of the PPD TB test. If the Quanti FERON-TB Gold or TSPOT.TB 
test is positive, th e patient will be considered to have latent TB. If the test is not negative, the test may be repeated once within 2 weeks of the initial value. If 
the repeat test results are again not negative, the patient will be considered to have latent TB.
iA chest x -ray will be taken at screening unless one has been obtained within 6 months prior to the study (provided the x -ray and/or repo rt are available for 
review).
jPatient- reported questionnaires will be administered via an electronic patient -reported outcomes (ePRO) device and should be administered prior to any 
clinical assessments.
kHBV DNA testing will be performed in patients who tested positive for HBcAb at screening. Patients who are HBcAb positive and HBV DNA negative at 
Visit 1 will require HBV DNA mon itoring every 3 months, at an ET visit, and at Visit 801, regardless of their HBsAb status. If the HBV DNA result is above 
the lower limit of quantification (LLOQ) , refer to S ection 7.1.2 and Section 8.4.4. For study sites in Japan (or elsewhere if required), if a patient is HBcAb 
positive and/or HBsAb positive andnegative for HBV DNA at Visit 1 , HBV DNA needs to be checked at least monthly and at the patient’s last visit.
lFor all women of childbearing potential, a serum pregnancy test (central laboratory) will be performe d at Visits 1 and 2. Urine pregnancy tests (local 
laborato ry) will also be performed at Visit 2 and at all subsequent study visits.
mTo confirm postmenopausal status for women ≥40 and <60 years of age who have had a cessation of menses, an FSH test will b e performed. Nonchildbearing 
potential is defined as an FSH ≥40 mIU/mL and a cessation of menses for at least 12 months.
nClinical chemistry will include the following values calculated from serum creatinine :  estimated glomerular filtration rate ( eGFR ; calculated using the 
Modification of Diet in Renal Disease [MDRD] isotope dilution mass spectrometry traceable method).
oFasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to sample collection. If a p atient att ends these visits in a 
nonfasting state, this will not be considered a protocol violation.
pAt Visit 2, one PK sample will be collected 15 to 30 minutes POST dose, as described in Section 8.5. Apart from this single PK sample, all other baseline 
laborato ry samples are taken PREdose.
qA single PK sample will be collected at Visit 4 and Visit 7 at any time  predose , as described in Section 8.5. To reduce the number of blood draws, the predose 
PK sample may be drawn at the same time as other labs required at the visit. If a patient arr ives at the clinic on Visit 4 or Visit 7 after having taken the dose, 
the PK sample should be drawn with other routine labs rando mly at any  time postdose.
rA single PK sample will be collected at Visit 5 between 1 and 3 hours postdose, as described in Sec tion 8.5.To reduce the number of blood draws, the 
postdose PK sample may be drawn at the same time as other routine labs required at the visit.  
sA single PK sample is to be collected, if possible, from patients who discontinue the study early. In the event of a ser ious adverse event ( SAE ), up to 
2additional blood samples may be taken at the investigator’s discretion. If collected, the PK samples should be collected after the reported event, 
approximately 6 hours apart and within 24 hours of the patient’s last dose.
I4V-MC-JAHHClinical Protocol Page 76
LY3009104Appendix 3. Clinical Laboratory  Tests
I4V-MC-JAHHClinical Protocol Page 77
LY3009104Clinical Laboratory Tests a
Hematology b Clinical Chemistry b
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Absolute reticulocyte count Total bilirubin
Mean cell volume (MCV) Direct bilirubin
Mean cell hemoglobin (MCH) Alkaline phosphatase (ALP)
Mean cell hemoglobin concentration (MCHC) 
Leukocytes (WBC)Alanine aminotransaminase (ALT)/serum glutamic 
pyruvic transaminase
Absolute count of 
Neutrophils, segmentedAspartate aminotransferase (AST)/serum glutamic 
oxaloacetic transam inase 
Neutrophils, juvenile (bands) Blood urea nitrogen (BUN)
Lymphocy tes Creatinine
Monocytes Estimated glomerular filtration rate (eGFR)c
Eosinophils Uric acid
Basophils Calcium
Platelets Glucosed
Cell morphology Albumin
Differential and blood smeareCreatine phospho kinase (CPK)
Total protein
Iron studies (iron, TIBC, and ferritin)
Lymphoc yte subsets (T, B, NK, and T -cell subsets) Lipid Profiled,f
Total cholesterol
Urinalysis b High -density lipoprotein cholesterol (HDL -C)
Color Low-density  lipoprotein cholesterol ( LDL -C)
Specific gravity Triglycerides
pH
Protein Other Tests
Glucose Serum pregnancy test (females only)g
Ketones Urine pregnancy test (females only)g
Blood Follicle -stimulating hormone ( FSH)(females only)h
Bilirubin Hepatitis B surface antigen (HBsAg)
Urobilinogen Hepatitis B surface antibody (HBsAb)
Leukocyte esterase Hepatitis B core antibody (HBcAb)
Nitrite Hepatitis C antibodyi
Urine creatinine HBV DNAk
Microscopic examination of sedimentjHuman imm unodeficiency virus (HIV) serology
PPD or QuantiFERON® -TB Gold, or T -SPOT®. TBl
Anti- nuclear antibody (ANA) Thyroid-stimulating hormone (TSH)
Anti-double -stranded DNA (anti -dsDNA) antibody High -sensitivity C -reactive protein (hsCRP)
Autoantibodies ( anti-RNP, anti-Sm, anti-SSA/Ro, 
anti-SSB/La)Stored serum, plasma, urine, mRNAm, and DNA 
samples for exploratory biomarker analyses
Antiphospholipid antibodies Serum immunoglobulins (IgG, IgA, IgM)
Complement C3 and C4 Baricitinib plasma concentration (PK sample)
Abbreviations:  HBV DNA = hepatiti s B virus deoxyribonucleic acid; mRNA = messenger ribonucleic acid; PK = 
pharmacokinetics; PPD = purified protein derivative; RBC = red blood cells; TIBC = total iro n binding capacity;
WBC = white blood cells.
aAll labs will be a ssayed/calculated by a Lilly-designated laboratory unless otherwise noted .
I4V-MC-JAHHClinical Protocol Page 78
LY3009104bUnscheduled blood chemistry (including CPK), hematology, and urinalysis panels may be performed at the 
discretio n of the investigator. If tests are done to ev aluate laboratory results to resume investigational product , 
samples must be assayed centrally.
ceGFR for serum creatinine will be calculated by the central laboratory using the Modification of Diet in Renal 
Disease (MDRD) isotope dilution mass spectromet ry traceable method. 
dFasting laboratory values for glucose and lipids will be required at baseline, Week 12, and Week 24. If a patient 
attends these visits in a nonfasting state, this will not be considered a protocol violation. These tests may be 
performed no nfasting at all other visits.
eDifferential and blood smear may be performed if necessary .
fLipid panel consists of direct HDL -C, trigly cerides, cholesterol, and LDL -C (calculation from Friedewald et al. 
1972).
gFor all women of childbearing potential, a serum pregnancy test (central laboratory) will be performed at Visit 1, 
and both urine (local laboratory) and serum pregnancy (central laboratory) tests will be performed at Visit 2 to 
determine study eligibility. Urine pregnancy tests (local laboratory) will also be performed at each subsequent 
study visit per the Schedule of Activities .
hTo confirm postmenopausal status for women ≥40 and <60 years of age, an FSH test will be performed. 
Nonchildbearing potential is defined as an FSH ≥40 mIU/mL and a cessation of menses for at least 12 months. 
iA positive hepatitis C antibody result will be confirmed with a positive hepatitis C virus result.
jMicroscopic examination of sediment will be performed if abnormalities are noted on the routine urinalysis.
kHBV DNA testing will be performed in patients who tested positive for HBcAb at screening. Patients who are 
HBcAb positive and HBV DNA negative at Visit 1 will require HBV DNA monitoring every 3 mont hs, at an 
early  termination ( ET
) visit, and at Visit 801, regardless of their HBsAb status. If the HBV DNA result is above 
the lower limit of quantification (LLOQ) , refer to Section 7.1.2 and Section 8.4.4. For study sites in Japan (or 
elsewhere if required), if a patien t is HBcAb positive and/or HBsAb positive andnegative for HBV DNA at 
Visit 1, HBV DNA needs to be checked at least monthly and at the patient’s last visit.
lPPD, QuantiFERON® -TB Gold, and T -SPOT®.TB t ests may be performed locally. Test will be required a t Visit 
1 only to determine eligibility of patient for the study. In countries where the QuantiFERON -TB Gold or T -
SPOT.TB test is available and, in the judgment of the investigator, medically preferred as an alternative to the 
PPD test for the evaluation o f mycobacterium tuberculosis (MTB) infection, either may be used instead of the 
PPD test (positive tests excluded).
mInterferon (IFN) signature will be assayed from stored mRNA sample.
I4V-MC-JAHHClinical Protocol Page 79
LY3009104Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly , or i ts desi gnee, CRP .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
ALP
ALT Anti -Nuclear Antibody (ANA) a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -Smooth Muscle Antibody (or anti -actin 
antibody) a
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspirate aminotransferase; 
CPK = creatinine phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = 
internatio nal no rmali zed ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
Leo Document ID = 4a1b1699-ff86-4f60-85c4-c62821a732f9
Approver: 
Approval Date & Time: 11-Dec-2015 20:06:16 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 11-Dec-2015 20:41:38 GMT
Signature meaning: Approved
PPD
PPD